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1. INTRODUCTION
Human papillomaviruses are small, double-strained DNA viruses that 
can infect cutaneous and mucosal epithelium in a large variety of vertebrates. 
Up to date, more than 200 papillomavirus types were isolated, 120 types from 
humans, half of them can infect genital tract [1].  
Human papillomaviruses cause warts and some type’s cervical cancer and its 
precancerous lesions [2]. 
The onset of molecular cloning of HPV genome in 1980s made possible the 
study of an individual viral genes. 
 Worldwide population prevalence of HPV among women ranges from 2-44% 
[3]. These wide variations are explained by the divergence in the age range of 
the studied population and the sensitivity of the DNA assays used for HPV 
detection. 
Age prevalence curve showed a clear peak in women under 25 years of age, 
with an subsequent decline, and increases again [4], with an second peak 
after, less prominent than first one and is observed in women older than 50 
years old [5]. 
Cervical cancer is the second most common cancer in women, whereas in 
developing countries where 80% of them occur, it is even a principal cancer in 
women. 
Nowadays, we have clear molecular and epidemiological data indicating that 
certain types of human papillomaviruses are the principal cause for cervical 
cancer [6,7]. This group is known as high risk HPV types (hr-HPVs). 
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1.1 Human papillomaviruses classification 
Human papillomaviruses are small, non-enveloped, circular double strained 
DNA viruses, with an approximately 8 kb in size. Papillomaviruses can 
primarily infect cutaneous epithelia end mucosa of humans and other higher 
vertebrates. 
Papillomaviruses (PV) were specified as a different family, Papillomaviridae, in 
the 7th Report of International Committee on Taxonomy of Viruses (ICTV).
Human papillomaviruses are classified in five genera, named by Greek 
alphabet letters: alfa, beta, gamma, mu and nu [8] [Figure 1].  
Human papillomaviruses DNA genome contain eight genes, encoding eight 
open reading frames (ORFs). 
The onset of molecular cloning of HPV genome in 1980s made possible the 
study of an individual viral genes. Nevertheless, only in 1990s the cultivation 
and propagation of viruses in organotopic cultures made possible studying the 
viral genetics of HPV. 
The availability of complete and partial genome sequences from a broad 
variety of PV types, as well as an increase in the number of PV isolates has 
emerged the need for taxonomic classification of Papillomaviruses [9].
Papillomaviruses have been traditionally referred as “types”. As the L1 ORF is 
best conserved gene in the structure of PVs, it has been used for the 
identification of new PV, as well as in classification and building up the 
polygenic tree. 
A Papillomavirus type is recognized if the complete genome has been cloned 
and the DNA of L1 gene is at least 10% different from other known PV type. 
Subtypes of papillomaviruses are defined if the differences in the genome of 
L1 are between 2-10%, whereas if there is less than 2% we are taking about 
the variant of PV [9]. 
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Figure 1. Classification of Papillomaviridae 
1.2 Structure and the genome of the HPV 
Papillomavirus as a small, non-enveloped DNA virus, containing the capsid 
that has two structural proteins, L1, 80% of total viral protein and L2. Viruses-
like particles (VLPs) can be produced by an expression of L1, alone or in 
combination with L2 [10,11].  
The genomes of all HPV types have around eight ORFs, each of them 
transcribed from the single DNA strain. The ORF has tree functional parts: 
- Early (E) region that encodes proteins E1-E7, essential for viral 
replication 
- Late (L) regions that encodes structural proteins L1 and L2, necessary 
for viral assembly 
4 
- Long control region (LCR), mostly as non-coding part, contains cis 
elements that are essential for the process of viral DNA replication and 
transcription [Figure2]. 
The E1 and E2 proteins directs the host cell factors to viral origin of replication 
[12,13] during the maintenance phase of the replication process, the E2 
ensures that viral genomes are partioneted into the daughter cells (14) E2 is 
also the main regulator of viral gene transcription. E2 can activate or, more 
often, can repress viral transcription [14]. E4 plays role in a late stages of the 
virus life cycle, whereas E5 can play role in both early and late phases, by 
facilitating the immune evasion, by downregulation surface expression of 
proteins engaged in antigen exposure [15]. The proteins E6 and E7, plays a 
decisive role  in carcinogenesis, by targeting different regulators of the cell 
cycle, like p53, pRb, Bak etc. [16,17].  These proteins are not well conserved, 
and both of them promotes cellular proliferation and inactivate cellular cycle 
checking points [18,19]. The In the HPV positive cancer-derived cells, the 
expression of oncoprotein E6 induces growth arrest followed by either
apoptosis or senescence. [20-22]. Therefore, its an indication that HPV-
positive cancers are “addicted” to E6 expression, in order to survive, so 
inhibiting the protein E6 key functions may lead to a promising strategy for 
counteracting the growth of HPV-positive tumors [Figure 2]. 
L1 and L2 proteins assemble in capsomers, and further forming 
icosahedral capsids around the HPV viral genome during the progeny virions 
[23]. 
5 
Figure 2. The genome of HPV 
1.3. HPV life cycle 
HPVs are highly epitheliotropic pathogens, and infection and viral cycle 
are completely reliant upon the expression of the complete process of 
keratinocyte differentiation. It is supposed that virus infects primitive basal 
keratinocytes, presumably at the site of micro injuries, which probably gain the 
stem cell phenotype during the wounding process [24,25]. All PVs induce 
proliferation of the infected cells. This proliferation mobilizes the cellular DNA 
replication and protein production machinery, which are hijacked by the virus 
to the benefit of its own replication [20,26-28]. 
Most HPV types that are designated as “low-risk” generate mild benign 
pathogenic effects, such as skin warts, mucosal lesions, or in the worst case, 
mucosal condylomas that require surgery [20,26,27]. However, for a subset of 
HPV types dubbed “high-risk”, viral genes sometimes do not get fully 
eradicated by the host. All or part of the viral genome remains maintained in at 
least one host cell, either in an episomal form or inserted in the host cell 
genome [29]. 
Human Papilloma Viruses are strongly associated with a group of 
malignancies, most notably cervical cancer (CC). The viral oncogenes have 
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the capability to promote, during a long period that may last up to three 
decades, further making changes to the infected cell, which may eventually 
lead to cancer [30]. Several studies have proposed the existence of multiple 
HPV target cells within the host epithelium.  
Acknowledged the anatomical observations that a lot of cervical
cancers are derived from the transformation zone (TZ), the association 
between infection of tissue stem cells and carcinogenesis has been proposed. 
There is an augmentative support for the hypothesis that stem cells of the TZ 
of the cervical epithelia are the primary site of persistent HPV infection [14,31]. 
The long after infection of injured basal cells, in HPV positive 
keratocytes and epithelial cells, suprabasal cells fail to back off from the cell 
cycle, and continue to support further the DNA synthesis and marker 
expression for cell proliferation [32], it is concept that there is a round of viral 
DNA replication, which is independent of the cell cycle and amplifies the viral 
copy number to about 50 to 100 copies per cell [33]. In the early phases of the 
high-risk HPVs life cycle, the expression of the potent E6 and E7 oncogenes is 
under control, and E6 and E7 transcripts of high-risk HPV types are barely 
detectable [34]. At the time when the infected keratinocyte move into the 
stratum spinosum initiating the cell cycle, then comes an prolonged 
upregulation of viral gene expression and the replication of viral DNA,
amplifying the viral copy number to thousands of copies per cell, gross 
expression of the E6 and E7 early genes, and late genes expression of from 
the late promoter, leading finally to HPV formation [35].
Studies have demonstrated that E6 and E7 are responsible for most of 
the proliferative and transforming events that lead to carcinogenesis [9,36]. 
Altogether, E6 and E7 exhibit anti-apoptotic and pro-proliferative effects, HPV-
induced cellular immortalization, similarly as cell adhesion and polarity, and 
cell differentiation-altering properties that facilitate a transient period of 
proliferation of the infected epithelial cells [37-40] [Figure 3].
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Figure 3. Role of E6 and E7 oncoproteins 
1.4. Immunobiology of human papillomaviruses
Human papilloma viruses are highly infectious agents, by inducing 
chronic infection that have systemic sequelae and not necessarily kill the host. 
To achieve this form of persistency, HPV has the specific immune evasion 
mechanism that inhibits the host’s detection of virus. Nevertheless, some 
epidemiological data suggest that the majority of ano-genital infections caused 
by oncogenic HPVs never become chronic [41]. In women, the incidence of 
new ano-genital infections by oncogenic HPVs decline with age, whereas 
persistence increases with age [42,43]. As HPVs are very diverse group in 
terms of genetics and its clinical presentation of the infection, it is very 
important reason why we cannot have a clear line between HPV acute and 
chronic infections. 
Virus infects primitive basal keratocytes, probably targeting stem cells, 
but high level of viral expression occur only in upper layers of the stratum 
spinosum and granulomatosum of squamous epithelia [44]. 
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For most the duration of the HPV infection cycle, there is little or no 
release into local milieu of proinflamatory cytokines which is important for 
antigen presenting cell (APC) activation and migration. 
hr-HPV infection encourages the migration of immune cell to the 
dermis. Important roles during the immune response to infection in the 
epidermis layer have the macrophages, natural killer cells (NK), T 
lymphocytes, B lymphocytes, Langerhans cells (LC), KCs and dendritic cells 
(DC).Infection with hr-HPVs could effectuate the immune system to get more 
tolerant to the infection, thereby generating a environment vulnerable to further 
infection and facilitating progression into cervical intraepithelial lesions. There 
are some mechanisms that have been proposed and proved, like: It is proven 
that hr-HPV remains silent for a long period of time; and its duplication and 
assembly do not necessarily lead to cytolysis or the cytopathic death of the 
host cells [45]. Then, hr-HPV inhibits the synthesis of interferon (IFN) through 
E6 and E7 oncoproteins by interfering with IFN signaling pathways [46]. On 
the other hand, hr-HPV infection promotes the infiltration of regulatory T cell 
(Treg) and interleukin (IL)-10 or transforming growth factor β (TGF-β)
production. Also, the hr-HPV infected cells express low levels of MHC class I, 
thereby resulting in impaired CTL function [47], and it compromises NK cell 
activation [48]. 
The ground for the progression from hr-HPV infection to cervical cancer 
is the impaired adaptive immunity. There are different immune cell profiles for 
the different stages of the disease progression in CIN and carcinogenesis. All 
the changes and alterations induced by hr-HPV infection are based in hr-HPV 
infection adapting the immune system to build a comfortable microenvironment 
for persistent infection and lesion progression [49]. 
The T cell activation is proven to be important in hr-HPV infection as 
shown in patients with HIV infection, compromised CD4+ T cells acts as the 
inducer for HPV-associated cancer appearance (45). In this case, the 
induction of incompetent CD4+ T cells infected by hr-HPV is the factor that 
promotes the progression of CIN lesion [50]. 
9 
hr-HPV infection can also change the balance between type 1 T-helper cells 
(Th1) and Th2 cell is another property of cellular immunity [51]. 
One of the mechanisms by which hr-HPV regulates T cell activation is 
supported by E6 and E7 expression, the oncoproteins which would upregulate 
the expression of another molecules in the infected cells, such as vascular cell 
adhesion molecule 1, intercellular adhesion molecule 1, and E-selectin 
(classical immunosuppressive molecules) [52]. 
Along with hr-HPV infection, immature DCs normally inhibit the 
activation of a proper immune response by CTLs and therefore making it 
easier lesion progression [53]. In patients with cervical cancer, the distribution 
of functional DCs are extremely low, or even completely absent. 
The central signals to initiate the start of the immune reaction in 
squamous epithelia are nonexistent [54]. There is no blood born viremic phase 
of HPV life cycle, the virus is practically invisible to the host, who remains 
ignorant of the pathogen for the long period of time. 
Viral capsides in epithelia should normally activate Langerhans cell 
(LC), but in the case of high risk HPVs, that doesn’t occur [55,56]. 
Despite the foremost attempts of the virus to putt-off the host defense 
system, most of HPV infection disappear with time. Infection with genital 
human papillomavirus (HPV), with both low- and high-risk types is a very 
common worldwide, but most infections resolve by the time, as a result of a 
cell-mediated immune response [57]. The majority of the low grade 
intraepithelial lesions are self-cleared as a result of a proper cell-mediated 
immune response headed against E2 and E6 oncoproteins [58-60]. Antibody 
concentrations achieved in animals and humans are low and many women do 
not show seroconversion [61,62].  
There is also well known that antibody response to HPV infection is 
type specific [63,64]. 
Although 80 to 90% of the genital HPV infections resolve with time, 
about 10-20% of individuals do not become HPV DNA negative and can 
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develop cervical intraepithelial neoplasia (CIN2/3) and cervical cancer. This 
condition is characterized by the overexpression of HPV E6 and E7 proteins in 
the divided cells, and have ability to resist both the innate and the adaptive 
antiviral immune defense.  Integration of HPV DNA into host chromosome is 
well known process that happen in high proportion in cervical cancers [65], are 
resistant to antiviral effect of IFN-b [66], and T-cell response to E2 and E6 are 
lost or reduced [67] [Figure 4].
Figure 4. The impact of HPV infection on squamous epithelia 
1.5. HPV transmission 
The most common way of transmission is horizontal one, mostly by 
sexual activity through mucosa to mucosa and skin to skin contact [68,69].
Fair-chance of infection per intercourse is not clearly known but is evident that 
is high [68]. As the transmission route is the same, around 20-30 % of women 
sampled for testing has had concurrent infections with more than one HPV 
type [70,71]. Most women have a high chance to be infected with at least one 
or several types of HPV during they life [72]. 
Another form of HPV transmission is vertical, when a parent pas the 
infection to its newborn offspring, including a special form of vertical 
transmission – perinatal infection. Transmission of HPV from mother to child, 
11 
known as vertical transmission, was first suggested in the 1950s [73-76]. 
Some authors detected over 70% of HPV transmission from mother to neonate 
[77]. 
Perinatal transmission of HPV infection has been unequivocally 
demonstrated for the rare disease juvenile respiratory papillomatosis [78].  
1.6. Clearance and persistence of HPV infection 
Most women infected with a specific HPV type will not show evidence of 
that same type 6–12 months later [79-81]. 
In a prospective study conducted among female college students, around 70% 
of women, within 12 months of follow-up period after incident HPV infection, no
longer had detectable levels of HPV DNA. After 18 months, over 80% 
appeared to have been cleared form the HPV infections [81]. Other cohort 
studies support this finding, several reporting a median duration of HPV 
detectability of approximately 1 year [80,82-84].
HPV 16 appears to have a particularly longer time of clearance relative 
[85] to other HPV types [86].
For papillomaviruses, most valuable evidence on latency come from 
animal models, where latency is considered a low-level viral genome 
maintenance in the basal layers of epithelia without a productive viral life cycle 
[87]. 
It is well known that on clearance time, other cofactors have an effect, 
like HPV genotype, host genetic background, age of sexual start-out, or other 
coinfections [88]. Nonetheless, our mechanistic knowledge is still far behind. 
For HPVs, regarding the latency development, two ways of reaching it have 
been proposed: one that claims that infections may directly enter latency by 
escaping an acute phase, or it may also arise after a productive phase without 
successful clearance [87,89]. In both cases, latency is directly linked to acute 
infection dynamics. 
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In the wider meta-communities context, latency can additionally be a
process that arises from diverse interactions between HPV and host cells. The 
molecular decision to start cell division in the basal layer is random and 
granted that the viral genome in order to replicate needs the cell division [90],
latency-reactivation episodes could be mechanistically understood to show 
randomness in the time lapses of basal cell mitotic activity, without necessarily 
demanding viral act upon the host cell. 
1.7. Prevalence of HPV infection 
The estimated population prevalence of HPV infection among women 
worldwide ranges from 2% to 44% [91]. The very wide variation in estimates is 
mostly interpreted by differences in the age range of the populations studied 
and the distinctness in sensitivity of the DNA assay used for detection of HPV 
infection, and type-specific HPV DNA prevalence among HPV-infected women 
[92].
Data derived from multiple international studies, have shown that the 
median oncogenic HPV prevalence among all women was 15.1%, while the 
median oncogenic HPV prevalence among women older than 30 was 9.2% 
[91]. The prevalence of HPV infection is highest among women at younger age 
and evidently tends to drop off with increasing age [93]. Most studies 
conducted in several different regions in the world, have shown a decrease in 
HPV prevalence with age, with a peak prevalence of HPV infection in women 
under age 25, a decrease among women aged 35–54 and a second peak after 
age 55 [5,94,95].  
1.8. HPV and cervical cancer 
Experiments trying to establish a relationship between HPV infection 
and cervical cancer were initiated in 1970 [96]. In 1976 Meisels et al. [97] 
claimed that koilocytotic cells found in cervical smears of patients with flat 
dysplastic lesions corresponds to the cytopathogenic changes of a 
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papillomavirus infection. Early in 1985 the selective transcription of E5 and E6 
genes in cervical cancer were established [98]. 
HPV is a prevalent pathogen, the epidemiology of which has mostly 
been studied in uterine cervix and the vagina. Major epidemiological studies 
identified the HPV16, HPV 18 and few others as a major risk factors for 
cervical Cancer [99,100]. 
The major steps known to be essential for cervical cancer 
carcinogenesis include: HPV infection, persistence of the infection, 
progression of precancerous lesions and eventually invasion. 
Among over 200 HPV types, there are more than 40 mucoso-tropic 
viruses that infect the anogenital and upper aerodigestive tract [101].
Approximately 15 are considered to be high-risk types, including HPV 
16,18,31,33,35,39,45,51, 52, 56, 58 and 68. Types 16 and 18 are most 
dangerous, since they cause more than 70% of cervical cancers. 
The worldwide incidence of cervical carcinoma is more than 530000 
cases per year, whereas mortality reaches 275000 deaths annually, of which 
approximately 85% occur in developing countries. Whereas, some authors 
have highlighted the elevated burden of cervical cancer in some South-
Eastern European counties, like Romania, Bulgaria and is failing in Greece, 
Croatia and Slovenia [102]. 
1.9. Other risk factors for HPV infection 
1.9.1. Number of sex partners 
The most unvarying risk factor for HPV infection is increased number of 
sex partners. Several studies of women have demonstrated strong 
associations between lifetime number of sex partners and genital HPV 
acquisition [103-105] and in men [106]. Furthermore, it has been demonstrated 
that a woman’s reported estimate of her lifetime number of sex partners is 
positively correlated with HPV infection in herself [105]. 
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1.9.2. Smoking 
HPV infection has been positively associated with the status of current 
smoking [107-109] and past smoking [110]. Many previous studies proved 
certain degree of association between cigarette smoking and prevalence, 
incidence, and persistence of HPV infections [111-116]. Another study 
investigating the relationship between smoking and oncogenic HPV infection 
could not found any correlation between number of cigarettes smoked per day 
and presence of HPV DNA [117]. Whereas, other studies investigating the 
relationship between smoking and HPV infection have failed to detect an 
association [118,119].  
1.9.3. Oral contraceptive use 
When taking about certain association between oral contraceptive (OC) 
use and HPV infection it is difficult to evaluate it correctly, due to the constant 
association between sexual activity and OC use. Many case-control studies 
has been shown that the use of oral contraceptives to be associated with 
cervical cancer and HPV positive prevalence [120,121]. Other study has found 
that after adjusting for some variables, like the age at first debut and lifetime 
number of sex partners, former OC users showed a borderline association with 
HPV 16, 18 and 31 seropositivity, while current OC users exhibited a 
borderline association with HPV 16 and HPV 18, but not with HPV 31 
seropositivity [122].  
Other studies have reported an association between cause and HPV 
DNA positivity only after adjusting for variables such as number of sex 
partners [123], but most studies have found no association [119,124]. 
1.9.4. Infection with multiple types 
The infection with multiple HPV types in one individual is not uncommon 
and several studies that have tried to determinate the role of multiple HPV
infections and HPV persistence [125,126] claim that infection with multiple 
HPV types was associated with persistence of HPV infection, a finding 
supported by Woodman et al. [127], who found that simultaneous infection 
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with HPV16 and another type resulted in longer duration of detectable HPV 16 
than did infection with HPV 16 alone. Concurrent multiple HPV genotypes 
were detected in 36.93% (95%CI: 30.15-44.27) of the patients [128]. 
1.9.5. Development of lesions in cervix 
Any of HPV types, oncogenic and non-oncogenic ones, can cause 
pathologies referred as low grade squamous intraepithelial lesions (LSIL) of 
the cervix, whereas most cervical lesions that are classified as high-grade SIL 
(HSIL), carcinoma in situ or invasive cancer results positive for oncogenic HPV 
types. HPV 16 or HPV 18 are found at about 70% of invasive cervical cancers 
[129] and about 90% of genital warts are caused by HPV 6 or HPV 11[130]. 
Persistent infection with HR HPV types is linked with an increasing 
probability of integration of the viral circular genome (episome) into the host 
chromosomes, leading to cancer development [131-133]. Integration of the 
viral genome coincide with the development of high-grade cervical 
intraepithelial neoplasia (CIN II/III) due to overexpression of the E6 and E7 
oncogenes [26].  
Some authors noticed a balanced rise in HPV 16 positivity and all the range 
thought the cervical diseases form NILM to cervical cancer in the all regions of 
the world [134].  
The incidence of HSIL appears to be quite high among women infected 
with oncogenic HPV. In a cohort of women with no prior history of SIL, and 
tested positive on HPV test, the 2-year cumulative incidence of biopsy-
confirmed HSIL was 28% and only 3% for women with no detectable HPV 
infection [135], others had an evidence of the predominance of HPV16 in HSIL 
lesions of the uterine cervix [128]. 
HPV 18, 45, and other types of alfa species have a potential for 
endocervical glandular lesions and cervical adenocarcinoma [136], pathologies 
that cannot be so precisely detected by cytological screening [137]. HPV 31, 
33 and 58 have been reported to be related with the higher risk for CIN3 than 
other non HPV 16 HR types [108,138]. 
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1.10. Prevention of HPV infection 
Some authors claimed that by promoting absence and use of condoms 
could reduce the risk for cervical cancer [139], but others found out there is no 
complete protection against HPV transmission by condom use because the 
male anogenital skin area could not be completely covered [140]. 
Today the most effective primary prevention against the HR HPV 
induced cancers in women is the vaccination against the certain types of HPV. 
The development of HPV L1 virus like particles (VLPs) vaccines is a 
tremendous advance in prevention against cervical cancer.  
The VLP-s in vaccines are small, irregular shaped structures, composted of 
HPV major capsid L1 protein manufactured by DNA recombinant technology 
[141,142]. The capsid contain no genetic material [143]. 
Currently there are in use three vaccines, bivalent HPV vaccine 
Cervarix (Glaxo Smith Kline) covers HPV 16 and HPV 18, qudrivalent HPV 
vaccine Gardasil (Merck), covering HPV 6,11,16,18 and recently approved 9 
valent HPV vaccine by Gardasil (Merck) is designed to protect against HPV 6 
and 11, and 7 high risk HPV types (HPV 16/18/31/33/45/52/58) most common 
types found in cervical cancer worldwide. Approximately 90% of CC cases are 
attributed to infection with 7 HR HPV types targeted by (vHPV vaccine) [144]. 
All vaccines are Vaccines are injected intramuscularly, hence HPV 
VLPs induces the production of neutralizing antibodies against the HPV 
[145,146]. 
Although the vaccination against HR HPV types is a promising feature in a 
fight against the cervical cancer, there is still a long way until it can cover a 
considerable number of women worldwide. 
Hence, the screening against the cervical cancer should be the primary 
focus in developing countries. The implementation of a proper and organized 
cytology-based cancer screening program, which enables to detect 
precancerous lesions in early stages has helped to decrease the incidence 
and mortality of cervical cancer. 
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HPV testing is also approved in primary screening in women older than 30 
years [147]. 
Within 2 years of a newly acquired infection, 60% of young women developed 
an antibody response to HPV-16, compared with only 4%–13% of men [148].
Compared with men, women tend to exhibit more-robust cell-mediated 
and humoral immune responses to infectious agents in general [149]. The 
most assertable explanation is that high levels of estrogen promote antibody 
production, thereby increases immunocompetence, whereas androgens such 
as testosterone, suppress immune function [150]. 
The main conclusion from these sero-epidemiological studies is that the 
antibody response to HPV16 proteins does not invariably occur during a 
natural HPV infection. For example, only in about half of the women with 
normal cytology and HPV DNA presence in their cervical epithelium, a humoral 
immune response to VLPs is induced. The VLP-specific antibodies are 
neutralizing and genotype-specific and have been crucial for the development 
of preventive HPV vaccines [151,152]. 
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2. HYPOTHESIS
To prove if HPV 16 and 18 are more prevalent high-risk HPV subtypes in 
Kosovar female population. 
3. AIMS AND THE PURPOSE OF THE RESEARCH
General aim: 
x To determine the prevalence of high risk HPV infection in Kosovar
women
Specific aims: 
x To determine the prevalence of specific high risk genotypes isolated in
our samples
x To identify the relationship between high risk HPV positive women and
histopathological findings in the women included in our study
x To determine the relationship  between the high risk HPV positive
women and other cofactors that may influence the on it, like:
- parity,
- pregnancy termination,
- women’s sexual activity
- use of contraceptives
- tobacco use
- their profession and family incomes,
- existence of previous sexually transmitted diseases
- other systemic or gynecological disorders
- their partner age and profession
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4. MATERIAL AND METHODS
4.1. Materials 
Our study has included 260 women, aged 18 to 65 years old, from the 
different regions of Kosovo that has been attending outpatient unit of the 
Department of Genecology and Obstetrics at the University Clinical Center of 
Kosovo, from August 2015 to February 2016. 
Prior to enrolment to the study, all of the women were provided written 
inform consent and completed a questionnaire containing general information 
about them and their partners, their parity, sexual behavior, use of 
contraceptives, tobacco and drug use, previous history of sexually transmitted 
diseases and their social and income. 
During the gynecological examination, to each women enrolled in the study, 
one cervical smear was obtained for cytological examination, and another 
cervical smear was stored in 1ml of Digene Specimen Transport Medium
(STM) (Qiagen, Hilden, Germany) at −20 °C for subsequent HPV typing.
Cytology: Cytological examination was performed by an experienced 
and licensed pathologist at the Institute of Pathology, University Clinical Center 
of Kosovo, University of Prishtina, who was unaware of the HPV status of the 
patients. 
From the group of women enrolled in the study, only 199 specimens 
where in the condition to be tested for HPV genotyping, the rest of tubes has 
been destroyed or not saved in the proper manner so we decided to exclude 
them from the study. 
HPV typing were performed in the University Hospital for Infectious Diseases, 
Zagreb, Croatia and the Institute of Microbiology and Immunology, Faculty of 
Medicine, University of Ljubljana, Slovenia. 
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4.2. Methods 
4.2.1. Cytology 
Each women enrolled in the study conventional PAP smear was 
performed. The results are classified regarding the Bethesda system. The 
group of women that showed no pathologies in the cytological results were 
grouped as NILM. The others were listed as ASCUS, ASC-H and 2 cases of 
cervical carcinoma were additionally confirmed by the histopathology. 
4.2.2. Detection of HPV DNA and HPV typing
Detection of hr-HPV DNA was performed using a clinically validated 
RealTime High Risk HPV test (RealTime) (Abbott, Wiesbaden, Germany), 
which enables concurrent individual typing for HPV16 and HPV18, as well as 
pooled detection of 12 other carcinogenic HPV types (HPV31, HPV33, HPV35, 
HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66, and 
HPV68), and also includes an internal process control for sample adequacy, 
DNA extraction, and amplification [153,154]. To amplify HPV targets a primer 
mix was used, consisting of 3 forward primers and 2 reverse primers targeting 
a conserved L1 region. Signal for 14 HR HPV genotypes (HPV 16, 18, 31, 33, 
35, 39, 45, 51, 52,56, 58, 59, 66, and 68) is generated with the use of 
fluorescent labelled probes. Internal Control (IC) amplicons are generated with 
a primer set targeting an endogenous human beta globin sequence. The 
Abbott RealTime hr-HPV assay detects the endogenous human beta globin 
sequence as sample validity control for cell adequacy, sample extraction and 
amplification efficiency. 
During the amplification reaction on the Abbott, the target DNA is 
amplified by DNA Polymerase in the presence of dNTPs and magnesium. 
In the Abbott RealTime hr-HPV assay, the DNA Polymerase is first activated at 
92°C for 10 minutes. During each subsequent round of thermal cycling, a high 
temperature is used to melt double-stranded DNA strands apart, followed by a 
low temperature where primers anneal to their respective targets and are 
extended to generate double-stranded DNA products. 
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Amplification of both targets (HPV and IC) takes place simultaneously in the 
same reaction. 
The target sequence for the Abbott RealTime hr-HPV assay is in the 
conserved L1 region of the HPV genomes.  
In addition to several other transport media [153], the assay has also 
been clinically validated for use with cervical specimens collected with Digene 
STM (Qiagen) [155,156].
In specimens positive for other carcinogenic HPVs, HPV typing was 
subsequently performed using the Linear Array HPV Genotyping Test (Roche 
LA) (Roche Molecular Diagnostics, Branchburg, NJ) and, if necessary, also 
with an HPV52 type-specific real-time PCR assay and an in-house 
GP5+/GP6+ PCR assay, as described previously [154, 157].
The Linear Array HPV Genotyping Test (Linear Array) (Roche 
Molecular Diagnostics, Pleasanton, CA) is a standardized HPV genotyping test 
used widely. Linear Array combines PCR-amplification and reverse-line blot 
hybridization for simultaneous detection of 36 individual HPV genotypes and 
one subtype, including all high risk HPV genotypes (HPV 16, HPV 18, HPV 31, 
HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 
59, HPV 68, HPV 73, and HPV 82) [158]. A pool of HPV primers present in the 
Master Mix is designed to amplify HPV DNA from 37 HPV genotypes14 
including 13 high risk genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
and 68). Capture probe sequences are located in polymorphic regions of L1 
bound by these primers. An additional primer pair targets the human s-globin 
gene to provide a control for cell adequacy, extraction and amplification. 
AmpliTaq Gold DNA Polymerase is utilized for “hot start” amplification of the 
HPV target DNA and the s-globin control. First, the PCR reaction mixture is 
heated to activate AmpliTaq Gold DNA polymerase, to denature the viral DNA 
and human genomic DNA and to expose the primer target sequences. As the 
mixture cools, the primers (both upstream and downstream) anneal to the 
target DNA. The AmpliTaq Gold DNA polymerase, in the presence of Mg2+ 
and excess dNTPs, extends the annealed primers along the target templates 
to produce an approximately 450 base pair double-stranded HPV target DNA 
molecule or a 268 base pair s-globin DNA molecule termed an amplicon. This 
process is repeated for a number of cycles, each cycle effectively doubling the 
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amount of amplicon DNA. Amplification occurs only in the region of the HPV 
genome or s-globin gene between the appropriate primer pair.  
The entire genome is not amplified. 
Following PCR amplification, the HPV and the s-globin amplicon are 
chemically denatured to form single-stranded DNA by the addition of 
Denaturation Solution. Aliquots of denatured amplicon are then transferred to 
the appropriate well of the typing tray that contains hybridization buffer and a 
single LINEAR ARRAY HPV Genotyping Strip that is coated with HPV and s-
globin probe lines. The biotin-labeled amplicon will hybridize to the 
oligonucleotide probes only if the amplicon contains the matching sequence of 
the complementary probe. 
In addition, the LINEAR ARRAY HPV Genotyping Strip is coated with 
one cross-reactive oligonucleotide probe that hybridizes with HPV genotypes 
33, 35, 52 and 58.  
Following the hybridization reaction, the LINEAR ARRAY HPV 
Genotyping Strip is stringently washed to remove any unbound material. 
Streptavidin-Horseradish Peroxidase Conjugate is then added to the strip. The 
strip is than washed in order to remove any unbound Streptavidin-Horseradish 
Peroxidase Conjugate and a substrate solution containing hydrogen peroxide 
and 3,3',5,5'-tetramethylbenzidine (TMB) is added to each strip. In the 
presence of hydrogen peroxide, the bound streptavidin-horseradish 
peroxidase catalyses the oxidation of TMB to form a blue coloured complex, 
which precipitates at the probe positions where hybridization occurs.  
The LINEAR ARRAY HPV Genotyping Strip is then read visually by 
comparing the pattern of blue lines to the LINEAR ARRAY HPV Genotyping 
Test Reference Guide [Figure 5a and Figure 5b].  
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Figure 5a. Genotyping strips produced after LINEAR ARRAY HPV testing 
Figure 5b. Genotyping strips produced after LINEAR ARRAY HPV testing 
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Because of intellectual property rights for HPV 52 detection, this 
genotype is identified using a cross-reactive HPV 52 probe that hybridizes also 
with HPV 33, HPV 35 and HPV 58 [159]. A sample is defined as HPV 52 
positive if it reacts with the cross-reactive probe, but not with the HPV 33, HPV 
35 or/and HPV 58 genotype-specific individual probes [160]. 
The assay was performed on a LightCycler 1.5 Real-time PCR 
instrument (Roche Diagnostics) under the following conditions: initial DNA 
polymerase activation at 95 ◦C for 10 min, followed by 45 cycles of 95 ◦C for 
10 s (denaturation), 60 ◦C for 30 s (annealing) and 72 ◦C for 1 s (extension). 
The temperature transition rate was set to 20 ◦C/s for each of the steps. 
Acquisition of the fluorescence signal was performed on the F1 (530 nm) 
channel at the end of the elongation step of each cycle. The final step 
consisted of cooling at 20 ◦C/s to 40 ◦C with a 30 s hold. The analytical 
sensitivity of the RT-PCR assay was evaluated using triplicates of serial 10-
fold plasmid dilutions spanning from 1×107 to 1×101 DNA copies per reaction 
and the detection limit was established to be at least 10 viral copies. The 95% 
detection limit was calculated by probit analysis The HPV DNA status was 
determined by sequencing GP5+/GP6+ or PGMY09/PGMY11 PCR products, 
as described previously [157] for PCR amplifications, up to 5_l (up to 100 ng) 
of each of the samples was used per 25_l reaction [160].
4.3. Statistical analyses
To assess the associations between sociodemographic characteristics 
and overall HPV infection the univariate and multiple logistic regression 
analyses were used. A likelihood ratio test was used to investigate the 
associations between sociodemographic characteristics and hr-HPV types. 
Associations with p < 0.05 were treated as statistically significant. Analyses 
were performed with SPSS, version 23. 
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5. RESULTS
5.1. General characteristics of the women included in the 
study
After we have excluded the samples that were damaged, a total of 199 
women, 20 to 63 years old, with a mean age of 41.8 years (SD ± 9.3 years) 
were included in the study [Table 1]. The majority of women has been 
declared as Albanian (198/199, 99.5%), most of them have graduated from a 
secondary school (107/199; 53.8%), 20,6% (44/199) has finished the higher 
education and the rest were with elementary school or less (51.199, 25.6%).  
The vast majority of them  were married (176.199, 88.4%), 6.5% 
(13/199) divorced or widow and only 5% (10/199) single, 71.9% (143/199) had 
no job, declared as housewives or farmers, 25.6% (51/199) were employed 
and 5 out of 199( 2.5%) were students. 
70.9% (141/199) of women included in the study lives in a small families (only 
parents and their children), 27.1% in a large families, whereas only 2% (4/199) 
lives alone. 
Most of the women has declared they have sufficient income (104/199, 
52.3%), 27.1% (54/199) have insufficient income and with good family 
incomes were 20.6% (41/199) [Table 1]. 
Only 25.1% (50/199) were smokers, with a mean (SD) number of cigarettes 
11.3. No women has been declared as alcoholic or drug user. 
Mean (SD) number of partner is 1.1. Partners mean age was 45.5 
years, 99% of them were of Albanian nationality, and the majority of them have 
at least finished the secondary school [Table 1].
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Table 1. Socio-demographic characteristics of women included in the 
study  
N = 199 (%)
(Mean) age (SD) 41.8 (9.3)
< 40 years old 79 (39.7)
> 40 years old 120 (60.3)
Education
finished elementary school or less 51 (25.6)
finished secondary school 107 (53.8)
more than secondary school 41 (20.6)
Employment status
Employed 51 (25.6)
housewife or farmer 143 (71.9)
Student 5 (2.5)
Marital status
Married 176 (88.4)
divorced/widow 13 (6.5)
Single 10 (5.0)
Family size
Single 4 (2.0)
small family (parents & children)     141 (70.9)
large family (parents, children and other family members) 54 (27.1)
Family income*
Insufficient 54 (27.1)
Sufficient 104 (52.3)
Good 41 (20.6)
Smoking 
Yes 50 (25.1)
No 149 (74.9)
Mean (SD) number of cigarettes  (n = 50) 11.3 (6.3)
Alcohol 0 (0)
Drugs 0 (0)
Partner’s mean age (SD) (n = 183) 45.5 (10.3)
Partner’s nationality
Albanian 197 (99)
Turk 1 (0.5)
Swiss 1 (0.5)
Partner’s education
elementary or less 51 (25.6)
Secondary 107 (53.8)
high education 41 (20.6)
Categorical and continuous variables are shown as frequencies (percentages) 
and as mean (standard deviation), respectively.*The family’s financial situation 
was evaluated by patients themselves. 
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The mean age of menarche was 13.7 years, and average age at first 
intercourse was 21.8 years, were 21.1%(42/199) have had they sexual debut 
before 19 years of age, 89.4% had given birth to one or more children and 
50.3% (100/199) had at least one abortion (pregnancy termination) [Table 2].
Only one third of the women (59/199. 29.9%), had previous regular 
gynecological examination, were 15.6% (31/199) declared other concomitant 
gynecological disease, 25.1% (50/199) with concomitant chronic diseases, and 
prior STD, 16.1% (32/199). 
The majority of the women (116/199. 58.3%) previously underwent PAP 
smear testing, were 33.7% of them had one year testing interval, whereas 
13.6% of them were testing every 3 years,  had a regular menstrual cycle 
(126/199; 63.3%), were not using contraception (166/199; 83.4%) [Table 2].
Table 2. Characteristics of women included in the study – health issues 
N = 199 (%)
Mean age (SD) of menarche 13.7 (1.48)
Age at first sexual intercourse
< 18 years old 31 (15.6)
t 18 years old 168 (84.4)
Mean (SD) number of partners 1.1 (0.27)
Delivery 
Yes 178 (89.4)
No 21 (10.6)
Mean (SD) number of deliveries (n = 178)
Pregnancy termination
3.2 (1.6)
Yes 100 (50.3)
No 99 (49.7)
Number of abortions
0 99 (49.7)
1 57 (28.6)
2 26 (13.1)
3 or more 17 (8.5)
Menstrual cycle
Regular 126 (63.3)
Irregular 40 (20.1)
Postmenopausal 33 (16.6)
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Contraception use 
Yes 33 (16.5)
no 166 (83.4)
Regular gynecological examination 59 (29.9)
Concomitant gynecological disease 31 (15.6)
Prior STD 32 (16.1)
Concomitant chronic disease 50 (25.1)
Previous PAP smear 116 (58.3)
Time of previous PAP smear (n =116)
1 year or less 67 (33.7)
2 years 2 (1)
3 years 27 (13.6)
4 years or more 20 (10.1)
* Data is shown as frequency (percentage) for categorical and as mean (SD) for
continuous variables. 
5.2. Cytology results 
The vast majority of women (165/199; 82.9%) had a normal cytological 
result (negative for intra-epithelial lesion or malignancy, NILM). Atypical 
squamous cells of undetermined significance (ASCUS) were detected in 
cervical specimens of 30/199 (15.1%) women and atypical squamous cells, 
cannot exclude high-grade squamous intraepithelial lesion (ASC-H), and 
cervical cancer were detected in two women, respectively [Table 3]. 
Table 3. Cytology results of the women involved in the research
N = 199 (%)
Negative for intra-epithelial lesion or malignancy (NILM)      165 (82.9)
Atypical squamous cells of undetermined significance (ASCUS)  30 (15.1)
Atypical squamous cells, cannot exclude high-grade squamous  
Intraepithelial lesion (ASC-H)        2 (1.0)
Cervical cancer      2 (1.0)
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5.3. Detection and typing of HPV infection
The crude overall prevalence of hr-HPV infection with any of the 
targeted 14 HPV types was estimated at 13.1% (26/199; 95% confidence 
interval (95% CI: 9.1–18.5%) [Table 4]. As shown in Table 4 and illustrated in 
Figure 6, infections with HPV16 were overall the most common, followed by 
HPV31 and HPV51, and HPV18. 
Among 26 hr-HPV positive women, 21 were as a single infection and 5 of them 
as a multiple hr-HPV infections.
Table 4. Overall distribution of hr-HPV types among 199 women from 
Kosovo 
HPV Type Single Multiple
Total
N %
Negative 173 86.9
Positive 21 5 26 13.1
16 6 1 7 3.5
18 3 - 3 1.5
31 4 - 4 2.0
33 1 - 1 0.5
45 1 - 1 0.5
51 2 2 4 2.0
52 2 - 2 1.0
53 1 1 2 1.0
56 1 - 1 0.5
58 - 1 1 0.5
62 1 1 2 1.0
66 1 1 2 1.0
67 - 1 1 0.5
73 - 1 1 0.5
84 - 1 1 0.5
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Figure 6. Percentages of identified hr-HPV types 
Similarly, HPV16 was also the most frequently detected HPV type in 
patients with NILM, followed by HPV31 and HPV51. Patients with ASCUS 
were most frequently infected with HPV18 [Table 5].
Both cervical cancer cases determined by the cytological examination 
were additionally confirmed using histopathology. Using Roche LA and an in-
house GP5+/GP6+ PCR assay, single HPV16 and HPV66-positive cervical 
specimens were additionally positive for HPV84 and HPV67, respectively, two 
HPV51-positive cervical specimens were additionally positive for HPV53 and 
HPV62, respectively, and the HPV58-positive cervical specimen was 
additionally positive for HPV6 and HPV73 [Table 6].
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5.4. Association between sociodemographic characteristics 
and HPV infection 
As shown in Table 7, using univariate logistic regression analysis to 
investigate potential differences in the sociodemographic characteristics of 
HPV-negative vs. HPV-positive patients, statistically significant associations 
with HPV infection were found only for women’s age (p = 0.015), age at the 
time of first sexual intercourse (p = 0.006), delivery (p = 0.026), and history of 
pregnancy termination (p = 0.033). Despite the fact that the prevalence of HPV 
infection was the highest in women 30 to 39 years old (21.2% (11/52); mean: 
20.8%; standard deviation (SD): ±6.4), followed by women 20 to 29 years old 
(19.1% (4/21); mean: 19.0%; SD: ±10.5), 40 to 49 years old (9.6% (8/83); 
mean: 9.6%; SD: ±4.2), and over 50 (7.0% (3/43); mean: 7.0%; SD: ±5.8) 
(Figure 7&8), the differences were not statistically significant (p = 0.127). 
However, women over 40 had lower odds for HPV infection (odds ratio (OR) = 
0.36; 95% CI: 0.15–0.84) [Table 7 and Figure 2].
Moreover, lower odds for HPV infection were also observed among 
women that were at least 18 years old at sexual debut (OR = 0.28; 95% CI: 
0.11–0.69), had given birth to at least one child (OR = 0.32; 95% CI: 0.11–
0.91), or had a history of pregnancy termination (OR = 0.39; 95% CI: 0.16–
0.95) [Table 7]. Due to the small number of units in the category of the 
dependent variable (HPV infection), only three independent variables (age at 
inclusion in the study: up to 40 years old and over 40, age at first sexual 
intercourse: below 18 and at least 18 years old or older, and history of 
delivering at least one child), were included in the multiple logistic regression 
analysis. When controlling for other variables in the model, all three 
independent variables were statistically significantly associated with HPV 
infection, with OR = 0.37 (95% CI: 0.15–0.94) and p = 0.036 for overall older 
age (over 40 years old), OR = 0.18 (95% CI: 0.06–0.50) and p < 0.001 for 
older age at sexual debut (at least 18 years old), and OR = 0.28 (95% CI: 
0.09–0.92) and p = 0.035 for history of delivering at least one child.  
3ϯ 
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Figure 7. Age-specific HPV prevalence with standard deviation among 
199 women from Kosovo included in the study
Figure 8.  Among women younger than 40 the prevalence is 20% (95% CI: 
11 – 29%) and among older 8% (95%CI: 3 – 13%). 
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Table 7. Association between socio-demographic characteristics and 
HPV infection (results of univariate logistic regression analysis) 
HPV-negative 
(n = 173)
HPV-positive 
(n = 26) OR (95% CI) P-value
(Mean) age (SD) 42.4 (9.2) 38.4 (9.9) 0.96 (0.91; 1) 0.044
< 40 years old 63 (36.4) 16 (61.5) 1
> 40 years old 110 (63.6) 10 (38.5) 0.36 (0.15; 0.84) 0.015
Education
finished elementary 
school or less 45 (26) 6 (23.1) 1
finished secondary school 92 (53.2) 15 (57.7) 1.22 (0.44; 3.36) 0.697
more than secondary 
school 36 (20.8) 5 (19.2) 1.04 (0.29; 3.69) 0.950
Employment status
Employed 44 (25.4) 7 (26.9) 1
housewife or farmer 125 (72.3) 18 (69.2) 0.91 (0.35; 2.31) 0.835
Student 4 (2.3) 1 (3.8) 1.57 (0.15; 6.18) 0.702
Marital status
divorced/widowed 10 (5.8) 3 (11.5) 1
Married 155 (89.6) 21 (80.8) 0.45 (0.11; 1.77) 0.244
Single 8 (4.6) 2 (7.7) 0.83 (0.11; 6.26) 0.859
Family size
Single 3 (1.7) 1 (3.8) 1
small family 
(parents&children) 124 (71.7) 17 (65.4) 0.41 (0.04; 4.18) 0.453
large family (parents, 
children and other family 
members) 46 (26.6) 8 (30.8) 0.52 (0.05; 5.66) 0.593
Family income*
Insufficient 47 (27.2) 7 (26.9) 1
Sufficient 88 (50.9) 16 (61.5) 1.22 (0.47; 3.18) 0.683
Good 38 (22) 3 (11.5) 0.53 (0.13; 2.19) 0.380
(Mean) age (SD) at first 
sexual intercourse 21.9 (4.2) 20.8 (5.4) 0.94 (0.84; 1.04) 0.230
< 18 years old 22 (12.7) 9 (34.6) 1
> 18 years old 151 (87.3) 17 (65.4) 0.28 (0.11; 0.69) 0.006
Delivery
No 15 (8.7) 6 (23.1) 1
Yes 158 (91.3) 20 (76.9) 0.32 (0.11; 0.91) 0.026
Pregnancy termination
No 81 (46.8) 18 (69.2) 1
Yes 92 (53.2) 8 (30.8) 0.39 (0.16; 0.95) 0.033
Menstrual cycle
Irregular 33 (19.1) 7 (26.9) 1
Regular 108 (62.4) 18 (69.2) 0.79 (0.30; 2.04) 0.620
Postmenopausal 32 (18.5) 1 (3.8) 0.15 (0.02; 1.27) 0.081
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Contraception
No 145 (83.8) 21 (80.8) 1
Yes 28 (16.2) 5 (19.2) 1.23 (0.43; 3.54) 0.697
Smoking
No 131 (75.7) 18 (69.2) 1
Yes 42 (24.3) 8 (30.8) 1.39 (0.56; 3.42) 0.477
Categorical and continuous variables are shown as frequencies (percentages) and as 
mean (standard deviation), respectively. *The family’s financial situation was 
evaluated by patients themselves. Abbreviations: OR (odds ratio), 95% CI (95% 
confidence interval). 
The results of the multiple logistic regression analysis therefore suggest 
that women younger than 40, who were younger than 18 at the time of first 
sexual intercourse and that have not yet given birth, are at greater risk for HPV 
infection [Figure 9&10]. 
The share of women according to important factors associated with 
HPV infection are summarized in Figure 9.  Among women that were HPV 
negative there is higher share of women with delivery or abortion in 
comparison to women that were HPV positive. In this group there is a higher 
share of women above 40 years old and women that were of age when having 
first sexual intercourse. There is also lower percentage of women that had 
more than one partner. 
Figure 9: Percentage of women by important factors associated with HPV 
infection. 
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Odds ratios for HPV infections with 95% confidence intervals for important 
factors are summarized in Figure 10. 
Figure 10:  Odds ratios with 95 % confidence intervals for all relevant 
parameters. 
For the multiple logistic regression the minimum sample size 
requirements according to  Agresti’s (2007) rule of thumb is 10 cases in the 
smaller category of dependent variable per independent variable. We have 26 
HPV positive cases therefore 2 to 3 independent variables can be included in 
the multiple logistic regression model.   
Further analysis showed that there is a statistically significant 
association between delivery and abortion (p = 0.002) and between age and 
delivery (p < 0.001). To avoid multicollinearity and comply with 1:10 rule, the 
final model will include three predictors that is current age (above 40 or at 
most 40), age at the first sexual intercourse (bellow 18 or 18 or more) and 
number of partners.  
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> 40 yrs old
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Abortion
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Results are shown in Table 8. All three predictors are statistically 
significantly associated with HPV infection. Risk factors associated with HPV 
are therefore first sexual intercourse when being younger than 18, being 40 or 
younger and having more than one partner.   
Table 8. Association between current age, age at 1st sexual intercourse, 
number of partners and HPV infection (results of multiple logistic 
regression model) 
OR (95% CI) P-value
> 40 year old 0.29 (0.11; 0.70) 0.007
> 18 years at the 1st sexual 
intercourse 0.22 (0.08; 0.59) 0.003
More than one partner 4.05 (1.20; 13.61) 0.024
5.5. Association between sociodemographic characteristics 
and hr-HPV types 
As shown in Table 9, the results of the likelihood ratio test suggested 
that women infected with HPV16 were older in comparison to women infected 
with other hr-HPV types (p = 0.037). In addition, all women infected with 
HPV16 have given birth to at least one child, whereas only 68.4% of women 
infected with other hr-HPVs had biological children (p = 0.036). Other 
characteristics were not statistically significantly associated with specific hr-
HPV types. 
39 
Table 9. Association between socio-demographic characteristics and hr-
HPV types (results of likelihood ratio test).  
Other HPV type
(n = 19) HPV16 (n = 7) P-value
Age
< 40 years old 14 (73.7) 2 (28.6) 0.037
> 40 years old 5 (26.3) 5 (71.4)
Education
finished elementary school 
or less 6 (31.6) 0 (0) 0.107
finished secondary school 10 (52.6) 5 (71.4)
more than secondary 
school 3 (15.8) 2 (28.6)
Employment status
Employed 5 (26.3) 2 (28.6) 0.725
housewife or farmer 13 (68.4) 5 (71.4)
Student 1 (5.3) 0 (0)
Marital status
Married 15 (78.9) 6 (85.7) 0.303
divorced/widowed 3 (15.8) 0 (0)
Single 1 (5.3) 1 (14.3)
Family size
Single 1 (5.3) 0 (0) 0.706
Small (parents&children) 12 (63.2) 5 (71.4)
Large (parents, children 
and other family members) 6 (31.6) 2 (28.6)
Family income*
Insufficient 6 (31.6) 1 (14.3) 0.652
Sufficient 11 (57.9) 5 (71.4)
Good 2 (10.5) 1 (14.3)
Age at first sexual intercourse
< 18 7 (36.8) 2 (28.6) 0.691
40 
> 18 12 (63.2) 5 (71.4)
Delivery
Yes 13 (68.4) 7 (100) 0.036
No 6 (31.6) 0 (0)
Pregnancy termination
Yes 6 (31.6) 2 (28.6) 0.882
No 13 (68.4) 5 (71.4)
Contraception
Yes 4 (21.1) 1 (14.3) 0.691
No 15 (78.9) 6 (85.7)
Smoking
Yes 6 (31.6) 2 (28.6) 0.882
No 13 (68.4) 5 (71.4)
*The family’s financial situation was evaluated by patients themselves.
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Comparing the results of high risk HPV positive women and their 
respective professions, we found out that the most affected group are women 
that works as a cleaner (37.5% of them are high risk HPV positive), followed 
by the hairdressers (25%), and students (20%) [Table 10].
Table 10. Correlation between the profession and HPV positivity 
HPV
Negative
HPV 
Positive Total
N % N % N %
Total 173 86.9 26 13.1 199 100.0
Profession
Cleaner 5 62.5 3 37.5 8 100.0
Clerk 2 100.0 - - 2 100.0
Commercial 2 100.0 - - 2 100.0
Cooker 1 100.0 - - 1 100.0
Economist 7 87.5 1 12.5 8 100.0
Farmer 1 100.0 - - 1 100.0
Hairdresser 3 75.0 1 25.0 4 100.0
Housewife 123 87.2 18 12.8 141 100.0
Journalist 1 100.0 - - 1 100.0
Chemist 1 100.0 - - 1 100.0
Lawyer 5 83.3 1 16.7 6 100.0
Linguist 1 100.0 - - 1 100.0
Nurse 11 91.7 1 8.3 12 100.0
Sociologist 1 100.0 - - 1 100.0
Student 4 80.0 1 20.0 5 100.0
Tailor 2 100.0 - - 2 100.0
Teacher 3 100.0 - - 3 100.0
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We have analyzed the high risk HPV samples and their relationship with 
the menarche and menstrual cycle regularity, and our results show no 
statistical significance regarding these variables [Table 11]. 
Table 11. Menarche and Menstrual cycle regularity and HPV positivity 
HPV 
Negative
HPV 
Positive Total
P-value
N % N % N %
Total 173 86.9 26 13.1 199 100.0
Menarche
10-11 9 90.0 1 10.0 10 100.0
P=0.95412-13 73
85.9 12 14.1 85 100.0
14-15 73 86.9 11 13.1 84 100.0
16+ 18 90.0 2 10.0 20 100.0
Menstrual cycle
Irregular 33 82.5 7 17.5 40 100.0
P=0.158Postmenopausal 32 97.0 1 3.0 33 100.0
Regular 108 85.7 18 14.3 126 100.0
After analyzing the use of contraception and the results of HPV positive 
women we did found statistical significance (p=0.045), and it is worthy to 
mention that the most affected women were those who use oral contraception 
pills with 26,7% resulting HPV positive, and none of them who uses condoms 
appeared to have high risk HPV infection [Table 12].  
Table 12. Contraception and HPV infection 
HPV 
Negative
HPV 
Positive Total
P-value
N % N % N %
Total 173 86.9 26 13.1 199 100.0
Contraception
Condom 10 100.0 - - 10 100.0
P=0.045
IUD 7 87.5 1 12.5 8 100.0
no contraception 145 87.3 21 12.7 166 100.0
oral 
contraceptives 11 73.3 4 26.7 15 100.0
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We have also analyzed the correlation between HPV infection and the 
previous history of cervical screening. We could not find any statistical 
significance at this point. Also, there was no statistical significance after 
analyzing the time interval between the cervical screening (PAP smear) and 
HPV infection [Table 13]. 
Most of the women included in our study, have declared that they had no 
regular gynecological examinations (140/199), but there was no statistical 
significance found regarding this variable and HPV infection [Table 13]. 
Table 13. Correlation between HPV infection and the previous
history of cervical screening
HPV 
Negative
HPV 
Positive Total
P-value
N % N % N %
Total 173 86.9 26 13.1 199 100.0
Have you performed PAP smear before?
no 71 85.5 12 14.5 83 100.0
P=0.805
yes 102 87.9 14 12.1 116 100.0
When you have performed PAP smear?
>3 yr 17 85.0 3 15.0 20 100.0
P=0.821
1 yr 58 86.6 9 13.4 67 100.0
2 yr 2 100.0 - - 2 100.0
3 yr 25 92.6 2 7.4 27 100.0
no 71 85.5 12 14.5 83 100.0
Do you have regular gynecological examinations?
no 124 88.6 16 11.4 140 100.0
P=0.389
Yes 49 83.1 10 16.9 59 100.0
44 
6. DISCUSSION
Cervical cancer (CC), as a preventable disease, still continuous to be 
the fourth most common cancer in women worldwide [161].   
In developed countries, good preventive programs are established
which enables women to get screened, making most pre-cancerous lesions of
the cervix diagnosed at early stages when they can easily be treated. Early
treatment prevents up to 80% of cervical cancers in developed countries [162].
Whereas, in developing countries, leak of an effective screening means that
the disease in these women is often not identified in time, leading to an
advance stages, including the cancer itself. In addition, possibilities for
treatment of such late-stage disease may be insufficient, resulting in a higher
rate of death from cervical cancer in these countries.
Unfortunately, in Kosovo, up to date we have no exact data for 
incidence, morbidity and mortality from cervical cancer. 
It is well known that HPV is a major cause for the development of Cervical 
Cancer [4,7,163]. Infections with over 40 HPV types from the clinically most 
important Alpha-PV genus are considered to be the most frequently sexually 
transmitted infections in both genders [164]. In addition, worldwide, up to 4.5% 
of incident cancer cases, including cervical, anogenital, and head and neck 
cancers, are etiologically associated with HPV infection [165]. 
The data for the specific high risk HPV types and its distribution are the 
most necessary tool for developing new tests in HPV screening and producing 
vaccines that will cover most of HPV high risk types [166,167].
Moreover, cervical cancer accounts for 83% of all HPV-related cancers, with 
the majority occurring in women originating from less-developed countries 
[168]. 
In female population from Kosovo, the crude overall prevalence of 
infection with any of the 14 HR-HPVs was estimated at 13.1%.
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But, our results, shows lower prevalence comparing the studies conducted in 
other neighbor countries, as FYROM with 35.7% [169] and Serbia (Vojvodina 
region) with 50.5% [170].
From our results, it turned out that HPV 16 is the most prevalent high 
risk genotype with 26.9% of all hr-HPV positive tested women. This result 
corresponds with most studies conducted worldwide, in Europe and the region 
[4,92,171]. The second most prevalent hr-HPV types were HPV 31 and HPV 
51 with 15.4%, each. HPV 18 comes as a fourth most prevalent type with 
11.5% of HPV positive cases tasted in our study.
The rest of hr-HPV types found in our study were HPV 52,53,62,66 with 7.7 % 
each, and less frequent types were HPV 33,45,56,58,67,73 and 84. 
Our results corresponds with the slightly difference with other results 
reported earlier from our neighbors, as in FYROM most prevalent hr-HPV were 
HPV 16, 31, 53 and 18, in Albania is HPV 16, 53, 31, 18, Vojvodina region in 
Serbia  HPV 16,31,51 and 52 [169,170,172].
The HPV 31 and 51 were also reported in other studies in Europe, 31 as a 
second most prevalent in Croatia [173], also Germany[174] and Netherland 
[175] reported HPV 51 as the second most prevalent high risk genotype.  
Also, one of our aims in the study was to analyze the hr-HPV positivity 
in correlation with cytological findings of the women included in the study. 
From our results we found out that from the overall prevalence of hr-HPVs is 
9.7 % among women with NILM (negative for intraepithelial lesion) in the 
cytology screening, 23.3 % were diagnosed with ASCUS; The two cases 
diagnosed with ASC-H  and  two other with SSC (confirmed also by the
histopathology), were all positive on hr-HPV (HPV 16 and HPV 18, 
respectively). 
Interestingly, in our study population the overall hr-HPV prevalence in 
NILM (9.7% (6.1-15.2) was lower than in studies on a total of 10,744 eligible 
women from other countries in Central and Eastern Europe (9.7%; 95% CI: 6.1 
– 15.2% vs. 18.0%; 95% CI: 17.0 – 19.0%, respectively) [171,176-183], with
the reported high incidence rates of cervical cancer and related mortality rates 
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[184]. Our results were concordant with those obtained in the largest study in 
the region to date, performed on 4,199 Slovenian women (hr-HPV prevalence 
of 10.7%; cervical cancer incidence rate per 100,000: 13.4; mortality rate due 
to cervical cancer per 100,000: 6.1) [184,185] as well as with global data (hr-
HPV prevalence of 10.4%; cervical cancer incidence rate per 100,000: 15.1; 
mortality rate due to cervical cancer per 100,000: 7.6) [4,184].
Because persistent infection with hr-HPVs is a necessary, but non-
sufficient, etiological factor of cervical cancer [186-188], several contributory 
factors have been described previously [189]. In this study, the results of the 
univariate and multiple logistic regression analyses suggested that women 
over 40 (univariate logistic regression: p = 0.015, OR = 0.36; multiple logistic 
regression: p = 0.036, OR = 0.37) were at lower risk for HPV infection.
Our results are concordant with global data [189,190], reporting that the 
incidence/prevalence of HPV infection peaks at a younger age (below 25–35 
years), soon after the start of sexual activity, and declines with age due to the 
spontaneous clearance of HPV infections [4,190].
In our study, statistically significant associations with HPV infection 
were found for age at the time of first sexual intercourse, the results of the 
univariate and multiple logistic regression analyses suggested that women 
who were older than 18 at sexual debut (univariate logistic regression: p =
0.006, OR = 0.28; multiple logistic regression: p < 0.001, OR = 0.18) are at 
lower risk acquiring HPV infection. Our findings   are in concordance with 
those of other authors that claim that the beginning of sexual activity in early 
age, enlarges the risk for HPV infection(190,191), but there are some authors 
that claimed the opposite [192,193].
Other findings that shows statistical significance in our study is the 
history of deliveries. Our data tells that women with a history of delivering at 
least one child (univariate logistic regression: p = 0.026, OR = 0.32; multiple 
logistic regression: p = 0.035, OR = 0.28) and the women with a history of 
pregnancy termination also have lower odds (p = 0.033, OR = 0.39) for HPV 
infection. Similarly as in our study, there are authors that has published before, 
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claiming that having more deliveries, increases the risk for HPV infection and 
cervical cancer. 
In other case control studies, a very strong link was found between cervical 
cancer, cervical intraepithelial lesions and an increasing number of 
pregnancies [108,194-196]. But also, some authors did not observe any 
association between parity and CIN [197,198], another author found out that in 
the hr-HPV positive women, childbirth but not pregnancy was a predictive for 
CIN3+ [199]. There are suggestions that high parity might increase the risk for 
CC because it maintains the transformation zone on exocervix for many years, 
being more exposed to HPV and other cofactors [200]. 
Interestingly, according to the likelihood ratio test, in comparison to 
women infected with other hr-HPV types, women infected with HPV16 were 
older (p = 0.037) and have given birth to at least one child (p = 0.036). 
Regarding the other factors analyzed in our study, like number of partners in 
life, very large number of women has declared that they had only one partner 
in a lifetime, which may be insincere answering, due to cultural background, 
were having more partners is still a taboo among middle age women in 
Kosovo.
From the results of multiple logistic regression, we found the statistical 
significance (p=0.024), were women having more than one partner are at 
higher risk for HPV infection.  Our results are similar to the one published 
earlier, confirming the importance of the risk that brings the greater number of 
partners on inquiring the HPV infection [201], thus leading to the risk for even 
multiple infections with hr-HPV-s. Some authors have observed a significant 
increased risk of cervical diseases in individuals with multiple sexual partners 
compared to individuals with few partners, both in non-malignant cervical 
disease and in ICC [202]. 
We did found statistical significance in contraceptive use among hr-HPV 
infected women (p=0.045). Majority of the women included in the study 
declared that they do not use any contraceptive method. Probably, this group 
of women uses coitus interruptus as a method of contraception, which is 
widely used by the couples in Kosovo. Among the participants that uses other 
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methods, women that uses oral contraceptives are the most affected by hr-
HPV infection. Whereas, the women that uses condom were all hr-HPV
negative. Many case-control studies has been shown that the use of oral 
contraceptives to be associated with cervical cancer and HPV positive 
prevalence [203,204]. Sex hormones can alter the immune response to HPV 
16 virus particles [205]. Hormonal contraception has been hypothesized to 
facilitate carcinogenesis mediated by HPV through increased expression of 
viral oncogenes [206,207], and tumor persistence and promotion [208,209]. 
The association between condom use and decreased risk for HPV 
infection has been described [210-212], whereas some authors claims that 
condom use may not be very effective in preventing HPV infection [213],
because HPV lives in the skin of pubic area [214].
All the women included in the study declared they are not alcoholic nor 
drug users. One quarter of them are active smokers. Our results do not show 
any statistical significance regarding tobacco use and HPV infection. Most of 
the recent epidemiological studies confirmed the positive association between 
smoking and the risk for cervical cancer development [107,109]. IARC 
classified tobacco as a cause of CC. Whereas, Syrjanen K at all [112],
concludes that cigarette smoking is not an independent risk factor of CIN2+. 
One explanation of an increased risk of HR-HPV infection among smokers is 
the mitogeneic effect of nicotine and cotinine, by causing DNA damage and 
also impair the host local immune defense mechanisms [215,216]. 
We also couldn’t find any statistical significance when analyzing HR-
HPV positive women and their marital status, their level of education, family 
size, employment, economical background, by analyzing their income, 
declared by themselves. Some authors have noticed that low income 
environment and impossibility to use proper hygienic resources for personal 
hygiene are at higher risk for developing cervical cancer [217]. 
Our study, also has failed to show any relationship between the 
menarche, menstrual cycle regularity and the risk for HPV infection. 
More studies, with larger number of participants, should be conducted to show 
any possible correlation of HPV infection and these variables. 
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We have analyzed the relationship between previous PAP test 
screenings, the intervals between screening and the HPV infection. 
In our findings we could not find any statistically significance on it. 
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7. CONCLUSIONS
To the best of my knowledge, this study is the first study reporting the 
hr-HPV prevalence and distribution of HPV types in Kosovo, as well as the 
relationship between the hr-HPV infection and other related socio-
demographic factors. 
Through the development of this project a series of results was obtained: 
a) The crude overall prevalence of hr-HPV infection with any of the
targeted 14 HPV types was estimated at 13.1% (26/199; 95%
confidence interval (95% CI): 9.1–18.5%).
b) Infections with HPV16 were overall the most common, with 26.9% of all
hr-HPV types identified, followed by HPV31 and HPV51, with 15.4%
each, and HPV18 with 11.5%.
c) In our study, multiple HPV types were detected in five cervical smears
(HPV16+HPV84, HPV66+HPV67, HPV51+53, HPV51+62, and
HPV6+58+73)
d) Similarly, HPV16 was also the most frequently detected HPV type in
patients with NILM, followed by HPV31 and HPV51. Patients with
ASCUS were most frequently infected with HPV18.
e) After analyzing the potential differences in the sociodemographic
characteristics of HPV-negative vs. HPV-positive patients, statistically
significant associations with HPV infection were found for women’s age
( univariate logistic regression: p = 0.015, OR = 0.36; multiple logistic
regression: p = 0.036, OR = 0.37). Women over 40 had lower odds for
HPV infection.
f) Statistically significant associations with HPV infection were found for
age at the time of first sexual intercourse (p = 0.006), where lower odds
for HPV infection were also observed among women who were older
than 18 at sexual debut (univariate logistic regression: p = 0.006, OR =
0.28; multiple logistic regression: p < 0.001, OR = 0.18).
g) Also, statistically significant associations with HPV infection were found
at women with a history of delivering at least one child (univariate
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logistic regression: p = 0.026, OR = 0.32; multiple logistic regression: p
= 0.035, OR = 0.28), they were at lower risk for HPV infection. 
h) The results of the univariate logistic regression analysis additionally
suggested that women with a history of pregnancy termination also
have lower odds (p = 0.033, OR = 0.39) for HPV infection.
i) Interestingly, according to the likelihood ratio test, in comparison to
women infected with other hr-HPV types, women infected with HPV16
were older (p = 0.037).
j) In addition, all women infected with HPV16 have given birth to at least
one child, whereas only 68.4% of women infected with other HR-HPVs
had biological children (p = 0.036).
k) After analyzing the use of contraception and the results of HPV positive
women we did found statistical significance (p=0.045), and it is worthy
to mention that the most affected women were those who use oral
contraception pills with 26,7% resulting HPV positive, and none of them
who uses condoms appeared to have high risk HPV infection.
l) Regarding the other factors analyzed in our study, like number of
partners in life, very large number of women has declared that they had
only one partner in a lifetime, which may be insincere answering, due to
cultural background, were having more partners is still a taboo among
middle age women in Kosovo. From the results of multiple logistic
regression, we found the statistical significance (p=0.024), were women
having more than one partner are at higher risk for HPV infection.
After the first 10 years of routine use of HPV vaccines, comprehensive clinical 
trials and real-life data have confirmed the vaccines’ safety and effectiveness.
Even though the introduction of HPV vaccination has the potential to 
substantially reduce the incidence of cervical cancer cases, the full effect on 
women of all ages will be detectable no sooner than after 30 years. Thus well-
organized cervical cancer screening programs will still play a crucial role in the 
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prevention of cervical cancer and bridging the gap until the full effect of HPV 
vaccines can be observed [219].  
In comparison to cytology-based screening, HPV-based screening is 
more effective and efficient for the prevention of invasive cervical cancer. 
Therefore, HPV testing is an invaluable part of guidelines for cervical cancer 
screening, triage, and follow-up after treatment. Even though more than 190 
distinct HPV tests and at least 127 test variants were commercially available in 
only a fraction of HPV tests fulfill the criteria for use in primary cervical cancer 
screening, with RealTime, used in this study, being one of them [220]. 
The World Health Organization suggests that, in countries without established 
cytology-based cervical cancer screening, HPV-based screening programs, in 
combination with the implementation of HPV vaccination, could further 
accelerate screening benefits and reduce the burden of cervical cancer. 
Despite the fact that a comprehensive strategy, including HPV 
vaccination and HPV-based cervical cancer screening, has been 
demonstrated to be cost-effective in nearly all countries, progress toward 
prevention is often hindered due to relatively low access to vaccines and
limited use of cervical cancer screening, especially in low-income countries 
[221]. 
We hope that the results of this study will also persuade the authorities to
implement nationwide cervical cancer screening and HPV vaccination 
programs in Kosovo. 
Our results are concordant with global data, reporting that the 
incidence/prevalence of HPV infection peaks at a younger age (below 25–35 
years), soon after the start of sexual activity, and declines with age due to the 
spontaneous clearance of HPV infections.  
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In conclusion, this study is the first study reporting the hr-HPV
prevalence and distribution of HPV types in Kosovo.  
Because more than 70% of cervical precancerous lesions identified in the 
study could have been prevented using nationwide HPV-based cervical cancer 
screening and HPV vaccination programs, it is of outmost importance to
implement both programs in the national health care system in Kosovo as
soon as possible.
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8. ABSTRACT IN CROATIAN
Ciljevi: Trenutačni sustav zdravstvene zaštite Kosova ne podržava 
organizirani nacionalni probir karcinoma vrata maternice i program cijepljenja 
protiv human papiloma virusa (HPV). Do sada, nisu dostupni pouzdani podaci 
o incidenciji i mortalitetu raka vrata maternice na Kosovu, takoder ni o
prevalencije visokorizičnih HPV-a i raspodjela HPV tipova. Cilj nam je utvrditi 
prevalenciju i raspodjelu visokorizičnih HPV tipova prije cijepljenja i procijeniti 
povezanost sociodemografskih obilježja i povećanog rizika od HPV infekcije u
žena s Kosova.
Metode: Detekcija DNK visokorizičnih HPV tipova u cervikalnim obriscima 
žena koje su bile na rutinskoj ginekološkoj i citološkoj obradi provedena je 
primjenom klinički validiranog HPV testa, Abbott RealTime HPV testa, Roche 
Linear Array HPV genotipizacijskog testa, HPV52 tip-specifičnog realnog PCR-
a i GP5 + / GP6 + / 68 PCR. 
Rezultati: Ukupna prevalencija svih HPV-a visokog rizika procijenjena je na 
13,1% (26/199, 95% intervala pouzdanosti (CI): 9,1-18,5%), pri čemu je 
HPV16 najčešći tip (7/26; 26,9 %), zatim HPV31 i HPV51, od kojih je svaki 
detektiran u 4/26 (15,4%) cervikalnih uzoraka, HPV18, detektiran u 3/26 
(11,5%) uzoraka, HPV52 i HPV66, svaki detektiran u 2/26 (7,7%) uzoraka , i 
HPV33, HPV45, HPV56 i HPV58, svaki detektiran u jednom (3,9%) uzorku. 
Žene iznad 40 godina (OR = 0,36), starije od 18 godina pri prvom spolnom 
odnosu (omjer vjerojatnosti (OR) = 0,28), one koji su rodile barem jedno dijete 
(OR = 0,32), i one koje su imale prestanak trudnoće (OR= 0,39) imale su niži
rizik za HPV infekciju. 
Zaključak: Obzirom na to da bi se na Kosovu moglo spriječiti više od 70% 
prekanceroznih lezija vrata maternice pomoću HPV cjepiva protiv raka vrata 
maternice i cjepiva protiv HPV-a na nacionalnoj razini, od najveće je važnosti 
što prije implementirati preventivne programe u nacionalnom zdravstvenom 
sustavu.  
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9. ABSTRACT IN ENGLISH
PhD thesis: High risk HPV infection in Kosovar female population 
PhD candidate: Pranvera Zejnullahu Raçi, MD
Mentor: Prof. Dr. Adriana Vince, MD, PhD 
Affiliations:
University of Zagreb, School of Medicine, University Hospital for Infectious 
diseases, Zagreb, Croatia. 
University Clinical Centre of Kosovo, Clinic of Obstetrics and Gynaecology, 
Prishitina, Republic of Kosovo. 
Objectives: Kosovo’s current health care system does not support organized 
nationwide cervical cancer screening and human papillomavirus (HPV) 
vaccination programs. To date, no reliable data are available on cervical 
cancer incidence and mortality in Kosovo, or on high-risk HPV (hr-HPV) 
prevalence and HPV type distribution. Our aim is to determinate the pre-
vaccination prevalence and distribution of hr-HPVs and to assesses the 
associations between sociodemographic characteristics and increased risk of
HPV infection in women from Kosovo.  
Methods: Detection of hr-HPV DNA was performed in cervical swabs of
women that underwent routine gynecological and cytological evaluation by
using a clinically validated Abbott RealTime High Risk HPV test, Roche Linear
Array HPV Genotyping Test, HPV52 type-specific real-time PCR and an in-
house GP5+/GP6+/68 PCR.  
Results: The crude overall prevalence of any of the hr-HPVs was estimated at
13.1% (26/199; 95% confidence interval (CI): 9.1–18.5%), with HPV16 being 
the most common type (7/26; 26.9%), followed by HPV31 and HPV51, each 
detected in 4/26 (15.4%) cervical specimens, HPV18, detected in 3/26 (11.5%) 
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specimens, HPV52 and HPV66, each detected in 2/26 (7.7%) specimens, and
HPV33, HPV45, HPV56, and HPV58, each detected in a single (3.9%) 
specimen. Women over 40 (OR = 0.36), older than 18 at sexual debut (odds 
ratio (OR) = 0.28), those that had delivered at least one child (OR = 0.32), and 
those that had a history of pregnancy termination (OR = 0.39) were at lower 
risk for HPV infection. 
Conclusion: Because more than 70% of cervical precancerous lesions could 
have been prevented in Kosovo using nationwide HPV-based cervical cancer 
screening and HPV vaccination, it is of outmost importance to implement both 
programs in the national health care system as soon as possible. 
57 
10. REFERENCES
1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de
Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV
types and proposal of taxonomic amendments. Virology. 2010 May; 25;
401(1):70-9.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to
Humans. Human papillomaviruses IARC Monogr Eval Carcinog Risks
Hum. 1995;64:1-378.
3. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical
cancer--burden and assessment of causality. J Natl Cancer Inst Monogr.
2003;(31):3-13. Review.
4. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et
al. Worldwide prevalence and genotype distribution of cervical human
papillomavirus DNA in women with normal cytology: a meta-
analysis. Lancet Infect Dis. 2007;7(7):453–459.
5. Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodríguez AC, Bratti
MC, et al. AgeǦrelated changes of the cervix influence human
papillomavirus type distribution. Cancer Res. 2006.
6. Muñoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugaza I, Gili M, et al.
The causal link between human papillomavirus and invasive cervical
cancer: a population-based case-control study in Colombia and Spain.
Int J Cancer. 1992 Nov 11;52(5):743-9.
7. Bosch FX, Muñoz N. The viral etiology of cervical cancer. Virus Res.
2002 Nov;89(2):183-90.
8. van Regenmortel, M.H.V., Fauquet, C.M., Bishop, D.H.L., Carstens,
E.B., Estes, M.K., Lemon, et al. Virus taxonomy. Seventh report of the
International Committee on Taxonomy of Viruses. Academic Press, San
Diego. 2000.1162 pp.
9. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H.
Classification of papillomaviruses. Virology. 2004 Jun 20;324(1):17-27.
58 
10. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1
major capsid protein self-assembles into virus-like particles that are
highly immunogenic. Proc Natl Acad Sci U S A. 1992 Dec
15;89(24):12180-4
11. Hagensee ME, Yaegashi N, Galloway DA.Self-assembly of human
papillomavirus type 1 capsids by expression of the L1 protein alone or by
coexpression of the L1 and L2 capsid proteins. J Virol. 1993
Jan;67(1):315-22
12. Kurg R, Tekkel H, Abroi A, Ustav M. Characterization of the functional
activities of the bovine papillomavirus type 1 E2 protein single-chain
heterodimers.J Virol. 2006 Nov;80(22):11218-25. Epub 2006 Aug 30
13. Stenlund A. E1 initiator DNA binding specificity is unmasked by selective
inhibition of non-specific DNA binding. EMBO J. 2003 Feb 17;22(4):954-
63.
14. McBride AA. The papillomavirus E2 proteins. Virology. 2013 Oct;445(1-
2):57-79. doi: 10.1016/j.virol.2013.06.006. Epub 2013 Jul 10.
15. DiMaio D, Petti LM. The E5 proteins. Virology. 2013 Oct;445(1-2):99-
114. doi: 10.1016/j.virol.2013.05.006. Epub 2013 May 31.
16. Tomaić V. Functional Roles of E6 and E7 Oncoproteins in HPV-Induced
Malignancies at Diverse Anatomical Sites. Cancers (Basel). 2016 Oct
19;8(10). pii: E95. Review.
17. Ganti K, Massimi P, Manzo-Merino J, Tomaić V, Pim D, Playford MP, et
al. Interaction of the Human Papillomavirus E6 Oncoprotein with Sorting
Nexin 27 Modulates Endocytic Cargo Transport Pathways. PLoS
Pathog. 2016 Sep 20;12(9):e1005854. doi: 
10.1371/journal.ppat.1005854. eCollection 2016 Sep
18. Vande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology.
2013 Oct;445(1-2):115-37. doi: 10.1016/j.virol.2013.04.026. Epub 2013
May 24.
19. Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013
Oct;445(1-2):138-68. doi: 10.1016/j.virol.2013.04.013. Epub 2013 May
31.
59 
20. Harden ME, Munger K. Human papillomavirus molecular biology. Mutat
Res Rev Mutat Res. 2017 Apr - Jun;772:3-12. doi: 
10.1016/j.mrrev.2016.07.002. Epub 2016 Jul 5.
21. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-
Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human
papillomavirus-positive cancer cells. Oncogene. 2003 Sep 
4;22(38):5938-45.
22. Ramirez J, Poirson J, Foltz C, Chebaro Y, Schrapp M, Meyer A, et al.
Targeting the Two Oncogenic Functional Sites of the HPV E6
Oncoprotein with a High-Affinity Bivalent Ligand. Angew Chem Int Ed
Engl. 2015 Jun 26;54(27):7958-62. doi: 10.1002/anie.201502646. Epub
2015 May 27.
23. Fehrmann F, Laimins LA. Human papillomaviruses: targeting
differentiating epithelial cells for malignant transformation. Oncogene.
2003 Aug 11;22(33):5201-7. Review
24. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanism of
genomic instability in cells infected with the high-risk human
papillomaviruses. PLoS Pathog. 2009 Apr;5(4):e1000397. doi:
10.1371/journal.ppat.1000397. Epub 2009 Apr 24.
25. Pinidis P, Tsikouras P, Iatrakis G, Zervoudis S, Kokouli Z, Bathou A et al.
Human Papilloma Virus' Life Cycle and Carcinogenesis. Maedica
(Buchar). 2016 Mar;11(1):48-54.
26. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The
biology and life-cycle of human papillomaviruses. Vaccine. 2012 Nov
20;30 Suppl 5:F55-70. doi: 10.1016/j.vaccine.2012.06.083.
27. Tommasino M. The human papillomavirus family and its role in
carcinogenesis. Semin Cancer Biol. 2014 Jun;26:13-21. doi:
10.1016/j.semcancer.2013.11.002. Epub 2013 Dec 4.
28. Mittal S, Banks L. Molecular mechanisms underlying human
papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutat
Res Rev Mutat Res. 2017 Apr - Jun;772:23-35. doi: 
10.1016/j.mrrev.2016.08.001. Epub 2016 Aug 5.
60 
29. McBride AA. Oncogenic human papillomaviruses. Philos Trans R Soc
Lond B Biol Sci. 2017 Oct 19;372(1732). pii: 20160273. doi:
10.1098/rstb.2016.0273.
30. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the
first century of human tumour virology. Nat Rev Cancer. 2010
Dec;10(12):878-89. doi: 10.1038/nrc2961. Epub 2010 Nov 24.
31. Iacovides D, Michael S, Achilleos C, Strati K. Shared mechanisms in
stemness and carcinogenesis: lessons from oncogenic viruses. Front 
Cell Infect Microbiol. 2013; 3: 66. 
doi:  10.3389/fcimb.2013.00066.Published online 2013 Dec 25.  
32. Jeon S, Allen-Hoffmann BL, Lambert PF Integration of human
papillomavirus type 16 into the human genome correlates with a
selective growth advantage of cells. J Virol. 1995 May;69(5):2989-9
33. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, et all.
Organization of human papillomavirus productive cycle during neoplastic
progression provides a basis for selection of diagnostic markers. J Virol.
2003 Oct;77(19):10186-201.
34. Doorbar J. Host control of human papillomavirus infection and disease.
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:27-41. doi:
0.1016/j.bpobgyn.2017.08.001. Epub 2017 Aug 12.
35. Gadducci A, Guerrieri ME, Greco C. Tissue biomarkers as prognostic
variables of cervical cancer. Crit Rev Oncol Hematol. 2013
May;86(2):104-29. doi: 10.1016/j.critrevonc.2012.09.003. Epub 2012
Sep 30.
36. Klingelhutz AJ, Roman A. Cellular transformation by human
papillomaviruses: lessons learned by comparing high- and low-risk
viruses. Virology. 2012 Mar 15;424(2):77-98. doi: 
10.1016/j.virol.2011.12.018. Epub 2012 Jan 27.
37. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT HPV-
16 E6 and E7 proteins cooperate to immortalise human foreskin
keratinocytes. EMBO J .1989: 8: 3905–3910.
38. Mantovani F, Banks L. The human papillomavirus E6 protein and its
contribution to malignant progression. Oncogene. 2001 Nov
26;20(54):7874-87.
61 
39. Münger K, Howley PM .Human papillomavirus immortalization and
transformation functions. Virus Res. 2002 Nov;89(2):213-28. Review.
40. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human
papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins.
Cancer Sci. 2007 Oct;98(10):1505-11. Epub 2007 Jul 23.
41. Schiffman M, Wentzensen N. Human papillomavirus infection and the
multistage carcinogenesis of cervical cancer. Cancer Epidemiol
Biomarkers Prev. 2013 Apr;22(4):553-60. doi: 10.1158/1055-9965.EPI-
12-1406.
42. Castle PE, Walker JL, Schiffman M, Wheeler CM. Hormonal
contraceptive use, pregnancy and parity, and the risk of cervical
intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women
with equivocal or mildly abnormal cytology, Int J Cancer. 2005 Dec
20;117(6):1007-12.
43. Muñoz N, Méndez F, Posso H, Molano M, van den Brule AJ, Ronderos
M, et al. Instituto Nacional de Cancerologia HPV Study Group.
Incidence, duration, and determinants of cervical human papillomavirus
infection in a cohort of Colombian women with normal cytological results.
J Infect Dis. 2004 Dec 15;190(12):2077-87. Epub 2004 Nov 22.
44. Doorbar J. Molecular biology of human papillomavirus infection and
cervical cancer. Clin Sci (Lond). 2006 May;110(5):525-41.
45. Stanley MA, Sterling JC. Host responses to infection with human
papillomavirus. Curr Probl Dermatol. 2014;45:58-74. doi:
10.1159/000355964. Epub 2014 Mar 13.
46. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human
papillomavirus and cervical cancer. Lancet. 2013 Sep 7;382(9895):889-
99. doi: 10.1016/S0140-6736(13)60022-7. Epub 2013 Apr 23.
47. Piersma SJ. Immunosuppressive tumour microenvironment in cervical
cancer patients. Cancer Microenviron. 2011 Dec;4(3):361-75. doi:
10.1007/s12307-011-0066-7. Epub 2011 May 31.
48. Jimenez-Perez MI, Jave-Suarez LF, Ortiz-Lazareno PC, Bravo-Cuellar
A, Gonzalez-Ramella O, Aguilar-Lemarroy A, et al. Cervical cancer cell
lines expressing NKG2D-ligands are able to down-modulate the NKG2D
62 
receptor on NKL cells with functional implications. BMC Immunol. 2012 
Feb 8;13:7. doi: 10.1186/1471-2172-13-7.
49. Song D, Li H, Li H, Dai J. Effect of human papillomavirus infection on the
immune system and its role in the course of cervical cancer. Oncol Lett.
2015 Aug;10(2):600-606. Epub 2015 May 29.
50. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K.  Evolving
immunosuppressive microenvironment during human cervical
carcinogenesis. Mucosal Immunol. 2008 Sep;1(5):412-20. doi:
10.1038/mi.2008.33. Epub 2008 Jul 2
51. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ,
et al. A shift to a peripheral Th2-type cytokine pattern during the
carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J
Clin Pathol. 2005 Oct;58(10):1096-100.
52. Lee YS, Lee CW, Song MJ, Ho EM, Kim CJ, Park TC, et al. Cell-
mediated immune response to human papillomavirus 16 E7 peptide
pools in patients with cervical neoplasia. Acta Obstet Gynecol Scand.
2011 Dec;90(12):1350-6. doi: 10.1111/j.1600-0412.2011.01277.x. Epub
2011 Oct 18.
53. Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune concept of
human papillomaviruses and related antigens in local cancer milieu of
human cervical neoplasia. J Obstet Gynaecol Res. 2007 Apr;33(2):103-
13.
54. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006
Mar 30;24 Suppl 1:S16-22.
55. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus
can escape immune recognition through Langerhans cell
phosphoinositide 3-kinase activation. J Immunol. 2005 Jun
1;174(11):7172-8.
56. Da Silva DM, Fausch SC, Verbeek JS, Kast WM .Uptake of human
papillomavirus virus-like particles by dendritic cells is mediated by
Fcgamma receptors and contributes to acquisition of T cell immunity. J
Immunol. 2007 Jun 15;178(12):7587-97.
57. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol.
2008 May;109(2 Suppl):S15-21. doi: 10.1016/j.ygyno.2008.02.003
63 
58. Coleman N, Stanley MA. Characterization and functional analysis of the
expression of vascular adhesion molecules in human papillomavirus-
related disease of the cervix. Cancer. 1994 Aug 1;74(3):884-92.
59. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM,
Franken KL, Geluk A, et al. Frequent detection of human papillomavirus
16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 2002
Jan 15;62(2):472-9.
60. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM,
Kwappenberg KM, Hassane S, et al. Frequent display of human
papillomavirus type 16 E6-specific memory t-Helper cells in the healthy
population as witness of previous viral encounter. Cancer Res. 2003 Feb
1;63(3):636-41.
61. Carter JJ, Wipf GC, Hagensee ME, McKnight B, Habel LA, Lee SK, et al.
Use of human papillomavirus type 6 capsids to detect antibodies in
people with genital warts. J Infect Dis. 1995 Jul;172(1):11-8
62. Dillner L, Zellbi A, Avall-Lundqvist E, Heino P, Eklund C, Pettersson CA,
et al. Association of serum antibodies against defined epitopes of human
papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident
cervical cancer. Cancer Detect Prev. 1995;19(5):381-93
63. Carter JJ, Koutsky LA, Hughes JP et al. Comparison of human
papillomavirus types 16, 18, and 6 capsid antibody responses following
incident infection. J Infect Dis 2000; 181.
64. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller
JT. A virus-like particle enzyme-linked immunosorbent assay detects
serum antibodies in a majority of women infected with human
papillomavirus type 16. J Natl Cancer Inst. 1994 Apr 6;86(7):494-9.
65. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key
event in cervical carcinogenesis. J Pathol. 2007 Aug;212(4):356-67.
Review
66. Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, Zhang
XY, et al. Interferon-beta treatment of cervical keratinocytes naturally
infected with human papillomavirus 16 episomes promotes rapid
reduction in episome numbers and emergence of latent integrants.
Carcinogenesis. 2006 Nov;27(11):2341-53. Epub 2006 Sep 14.
64 
67. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren
GJ, Melief CJ, et al. Human papillomavirus type 16-positive cervical
cancer is associated with impaired CD4+ T-cell immunity against early
antigens E2 and E6. Cancer Res. 2004 Aug 1;64(15):5449-55.
68. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6:
Epidemiology and transmission dynamics of genital HPV infection.
Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61. Epub 2006 Jun 2.
69. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL,
et al. Genital transmission of HPV in a mouse model is potentiated by
nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007 Jul;13(7):857-
61. Epub 2007 Jul 1.
70. Mendez F, Munoz N, Posso H, Molano M, Moreno V, van den Brule AJ,
et al. Instituto Nacional de Cancerologia. Human Papillomavirus Study
Group Cervical coinfection with human papillomavirus (HPV) types and
possible implications for the prevention of cervical cancer by HPV
vaccines. J Infect Dis. 2005 Oct 1;192(7):1158-65. Epub 2005 Aug 29.
71. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM;
ALTS Group. A 2-year prospective study of human papillomavirus 
persistence among women with a cytological diagnosis of atypical 
squamous cells of undetermined significance or low-grade squamous 
intraepithelial lesion. J Infect Dis. 2007 Jun 1;195(11):1582-9. Epub 2007 
Apr 16. 
72. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus
infections. J Clin Virol. 2005 Mar;32 Suppl 1:S16-24.
73. Hajek EF. Contribution to the aetiology of laryngeal papilloma in
children. J Laryngol Otol. 1956 Mar;70(3):166-8.
74. Cason J, Kaye JN, Jewers RJ, Kambo PK, Bible JM, Kell B, et al.
Perinatal infection and persistence of human papillomavirus types 16
and 18 in infants. J Med Virol. 1995 Nov;47(3):209-18.
75. Puranen M, et al Vertical transmission of human papillomavirus from
infected mothers to their newborn babies and persistence of the virus in
childhood. . Am J Obstet Gynecol. 1996.
65 
76. Rombaldi R, Serafini E, Mandelli J, Zimmermann E, Losquiavo K.
Perinatal transmission of human papilomavirus DNA. Virol J. 2009; 6: 83.
Published online 2009 Jun 21. doi:  10.1186/1743-422X-6-83
77. Gajewska M, Wielgos M, Kamiński P, Marianowski P, Malejczyk M,
Majewski S, et al. The occurrence of genital types of human
papillomavirus in normal pregnancy and in pregnant renal transplant
recipients. Neuro Endocrinol Lett. 2006 Aug;27(4):529-34.
78. Dillner J. The serological response to papillomaviruses. Semin Cancer
Biol. 1999 Dec;9(6):423-30.
79. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific
DNA and RNA persistence--implications for cervical disease progression
and monitoring. J Med Virol. 2004 May;73(1):65-70.
80. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et
al. Epidemiology of acquisition and clearance of cervical human
papillomavirus infection in women from a high-risk area for cervical
cancer. J Infect Dis. 1999 Nov;180(5):1415-23
81. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of
cervicovaginal papillomavirus infection in young women. N Engl J Med.
1998 Feb 12;338(7):423-8.
82. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander
E, et al. Human papillomavirus infection is transient in young women: a
population-based cohort study. J Infect Dis. 1995 Apr;171(4):1026-30.
83. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T,
et al. Persistence of type-specific human papillomavirus infection among
cytologically normal women. J Infect Dis. 1994 Feb;169(2):235-40.
84. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et all.
Natural history of cervical human papillomavirus infection in young
women: a longitudinal cohort study. Lancet. 2001 Jun 9;357(9271):1831-
6.
85. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus
infections. J Clin Virol. 2005 Mar;32 Suppl 1:S16-24.
86. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy
A, et al. The natural history of type-specific human papillomavirus
66 
infections in female university students. Cancer Epidemiol Biomarkers 
Prev. 2003 Jun;12(6):485-90.
87. Maglennon GA, McIntosh PB, Doorbar J. Immunosuppression facilitates
the reactivation of latent papillomavirus infections. J Virol. 2014
Jan;88(1):710-6. doi: 10.1128/JVI.02589-13. Epub 2013 Oct 30.
88. Ferenczy A, Franco E. Persistent human papillomavirus infection and
cervical neoplasia. Lancet Oncol. 2002 Jan;3(1):11-6.
89. Doorbar J. Latent papillomavirus infections and their regulation. Curr
Opin Virol. 2013 Aug;3(4):416-21. doi: 10.1016/j.coviro.2013.06.003.
Epub 2013 Jun 29.
90. Reinson T, Henno L, Toots M, Ustav M Jr, Ustav M. The Cell Cycle
Timing of Human Papillomavirus DNA Replication. PLoS One. 2015 Jul
1;10(7):e0131675. doi: 10.1371/journal.pone.0131675. eCollection 2015.
91. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical
cancer--burden and assessment of causality. J Natl Cancer Inst Monogr.
2003;(31):3-13.
92. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S.
Cervical human papillomavirus prevalence in 5 continents: meta-analysis
of 1 million women with normal cytological findings. J Infect Dis. 2010
Dec 15;202(12):1789-99. doi: 10.1086/657321. Epub 2010 Nov 10.
93. Chan PK, Ho WC, Wong MC, Chang AR, Chor JS, et al. Epidemiologic
risk profile of infection with different groups of human papillomaviruses. J
Med Virol. 2009:81: 1635–1644.
94. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales
J, et al. Population-based study of human papillomavirus infection and
cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000 Mar
15;92(6):464-74.
95. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et
al. Variations in the ageǦspecific curves of human papillomavirus
prevalence in women worldwide. Int J Cancer 2006; 119: 2677–84.
96. zur Hausen H . Human papillomaviruses and their possible role in
squamous cell carcinomas. Curr Top Microbiol Immunol. 1977;78:1-30.
67 
97. Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina. I.
Cytologic patterns. Acta Cytol. 1976 Nov-Dec;20(6):505-9.
98. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau
A, et al. Structure and transcription of human papillomavirus sequences
in cervical carcinoma cells. Nature. 1985 Mar 7-13;314(6006):111-4.
99. Muñoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugaza I, Gili M, et al.
The causal link between human papillomavirus and invasive cervical
cancer: a population-based case-control study in Colombia and Spain.
Int J Cancer. 1992 Nov 11;52(5):743-9
100. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical 
cancer--burden and assessment of causality. J Natl Cancer Inst Monogr.
2003;(31):3-13
101. de Villiers EM, Gunst K, Stein H, Scherübl H. Esophageal squamous cell 
cancer in patients with head and neck cancer: Prevalence of human 
papillomavirus DNA sequences. Int J Cancer. 2004 Mar 20;109(2):253-8.
102. Arbyn M, Primic-Zakelj M, Raifu AO, Grce M, Paraskevaidis E,
Diakomanolis E, et al. The burden of cervical cancer in south-east 
Europe at the beginning of the 21st century. Coll Antropol. 2007 Apr;31 
Suppl 2:7-10. 
103. Tarkowski TA, Koumans EH, Sawyer M, Pierce A, Black CM, Papp JR,
et al. Epidemiology of human papillomavirus infection and abnormal 
cytologic test results in an urban adolescent population. J Infect Dis.
2004 Jan 1;189(1):46-50. Epub 2003 Dec 22.
104. Shi R, Devarakonda S, Liu L, Taylor H, Mills G. Factors associated with 
genital human papillomavirus infection among adult females in the 
United States, NHANES 2007-2010. BMC Res Notes. 2014 Aug 
18;7:544. doi: 10.1186/1756-0500-7-544 
105. Feixue Wei, Kai Yin, Xin Wu, Jian Lan, Shoujie Huang, Wei Sheng, et al.
Human papillomavirus prevalence and associated factors in women and 
men in south China: a population-based study. Emerg Microbes Infect.
2016 Nov; 5(11): e119. Published online 2016 Nov 23. 
doi:  10.1038/emi.2016.118. 
106. Svare EI, Kjaer SK, Worm AM, Osterlind A, Meijer CJ, van den Brule AJ.
Risk factors for genital HPV DNA in men resemble those found in 
68 
women: a study of male attendees at a Danish STD clinic. Sex Transm 
Infect. 2002 Jun;78(3):215-8.
107. Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N,
et al. Smoking as a major risk factor for cervical cancer and pre-cancer: 
results from the EPIC cohort. Int J Cancer. 2014 Jul 15;135(2):453-66. 
doi: 10.1002/ijc.28666. Epub 2014 Jan 6. 
108. Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA,
et al. Human papillomavirus cofactors by disease progression and 
human papillomavirus types in the study to understand cervical cancer 
early endpoints and determinants. Cancer Epidemiol Biomarkers Prev.
2009 Jan;18(1):113-20. doi: 10.1158/1055-9965.EPI-08-0591. 
109. Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, et 
al. International Collaboration of Epidemiological Studies of Cervical 
Cancer, Carcinoma of the cervix and tobacco smoking: collaborative 
reanalysis of individual data on 13,541 women with carcinoma of the 
cervix and 23,017 women without carcinoma of the cervix from 23 
epidemiological studies. Int J Cancer. 2006 Mar 15;118(6):1481-95. 
110. Rohan T, Mann V, McLaughlin J, Harnish DG, Yu H, Smith D, et al.
PCR-detected genital papillomavirus infection: prevalence and 
association with risk factors for cervical cancer. Int J Cancer. 1991 Dec 
2;49(6):856-60.
111. Vaccarella S, Herrero R, Snijders PJ, et al. Smoking and human 
papillomavirus infection: pooled analysis of the International Agency for 
Research on Cancer HPV Prevalence Surveys. Int J Epidemiol. 
2008;37:536–46.
112. Syrjanen K, Shabalova I,Petrovichev N,et al. Smoking is an independent 
risk factor for oncogenic human papillomavirus (HPV) infections but not
for high-grade CIN. Eur J Epidemiol. 2007;22:723–35 
113. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-
specific human papillomavirus infection and cervical neoplasia in
Guanacaste, Costa Rica. J Infect Dis. 2005;191:1796–807 
69 
114. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance 
and predictors of human papillomavirus infection in women. CMAJ 
2003;168:421–5.
115. Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors 
associated with clearance of type-specific cervical human papillomavirus 
infections in a cohort of university students. Cancer Epidemiol 
Biomarkers Prev. 2005;14:1149–56. 
116. Molano M, Van den Brule A, Plummer M, et al. Determinants of
clearance of human papillomavirus infections in Colombian women with
normal cytology: a population-based, 5-year follow-up study. Am J
Epidemiol. 2003;158:486–94.
117. Harris TG, Kulasingam SL, Kiviat NB,et al. Cigarette smoking, oncogenic 
human papillomavirus, Ki-67 antigen, and cervical intraepithelial 
neoplasia. Am J Epidemiol. 2004;159:834–42
118. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as 
determinants of cervical HPV infection and of CIN3 among those 
infected: a case-control study nested within the Manchester cohort. Br J 
Cancer. 2000:88: 1565–1572. 
119. Burk RD, Ho GYF, Beardsley L, Lempa M, Peters M, Bierman R. Sexual 
behavior and partner characteristics are the predominant risk factors for 
genital human papillomavirus infection in young women. J Infect Dis.
1996;174:679-689.
120. Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A, et al. The 
association of hormonal contraceptive use and HPV prevalence. Int J 
Cancer. 2011 Jun 15;128(12):2962-70. doi: 10.1002/ijc.25628. Epub 
2010 Oct 26. 
121. International Collaboration of Epidemiological Studies of Cervical 
Cancer. Appleby P, Beral V, Berrington de González A, Colin D,
Franceschi S, et al. Cervical cancer and hormonal contraceptives: 
collaborative reanalysis of individual data for 16,573 women with cervical 
cancer and 35,509 women without cervical cancer from 24 
epidemiological studies. Lancet. 2007 Nov 10;370(9599):1609-21. 
70 
122. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human 
papillomavirus 16, 18, 31, and 45 in a population-based cohort of
10,000 women in Costa Rica. Br J Cancer. 2003;89:1248–54.
123. Santos Filho MV, Gurgel AP, Lobo CD, Freitas AC, Silva-Neto JC, Silva 
LA. Prevalence of human papillomavirus (HPV), distribution of HPV 
types, and risk factors for infection in HPV-positive women. Genet Mol 
Res. 2016 Jul 14;15(2). doi: 10.4238/gmr.15028315.
124. Green J,  Berrington de Gonzalez A,  Smith J S,  Franceschi S, Appleby
P,  Plummer M, et al. Human papillomavirus infection and use of oral 
contraceptives. Br J Cancer. 2003 Jun 2; 88(11): 1713–1720.  
125. Ho GY, Palan PR, Basu J, et al. Viral characteristics of human 
papillomavirus infection and antioxidant levels as risk factors for cervical 
dysplasia. Int J Cancer. 1998;78:594–9.
126. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan 
TE, et all. Human papillomavirus infections with multiple types and risk of 
cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006 
Jul;15(7):1274-80.
127. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al.
Natural history of cervical human papillomavirus infection in young 
women: a longitudinal cohort study. Lancet. 2001 Jun 9;357(9271):1831-
6.
128. Beca F, Pinheiro J, Rios E, Pontes P, Amendoeira I. Genotypes and 
prevalence of HPV single and multiple concurrent infections in women 
with HSIL. Diagn Cytopathol. 2014 Nov;42(11):919-23. doi: 
10.1002/dc.23143. Epub 2014 Mar 13.
129. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah 
KV, et al. Epidemiologic classification of human papillomavirus types 
associated with cervical cancer. International Agency for Research on 
Cancer Multicenter Cervical Cancer Study Group. N Engl J Med. 2003 
Feb 6;348(6):518-27.
130. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, et 
al. Human papillomavirus (HPV) type distribution and serological 
response to HPV type 6 virus-like particles in patients with genital warts.
J Clin Microbiol. 1995 Aug;33(8):2058-63
71 
131. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic 
review of genomic integration sites of human papillomavirus genomes in 
epithelial dysplasia and invasive cancer of the female lower genital tract. 
Cancer Res. 2004 Jun 1;64(11):3878-84. 
132. Xu M, Katzenellenbogen RA, Grandori C, Galloway DA. An unbiased in 
vivo screen reveals multiple transcription factors that control HPV E6-
regulated hTERT in keratinocytes. Virology. 2013 Nov;446(1-2):17-24. 
doi: 10.1016/j.virol.2013.07.014. Epub 2013 Aug 8. 
133. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. 
Genome-wide analysis of HPV integration in human cancers reveals 
recurrent, focal genomic instability. Genome Res. 2014 Feb;24(2):185-
99. doi: 10.1101/gr.164806.113. Epub 2013 Nov 7.
134. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et
al. Human papillomavirus types in 115,789 HPV-positive women: a 
meta-analysis from cervical infection to cancer. Int J Cancer. 2012 Nov 
15;131(10):2349-59. doi: 10.1002/ijc.27485. Epub 2012 Mar 20. 
135. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, 
Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial 
neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J 
Med. 1992 Oct 29;327(18):1272-8.
136. Clifford G, Franceschi S. Members of the human papillomavirus type 18 
family (alpha-7 species) share a common association with 
adenocarcinoma of the cervix. Int J Cancer. 2008 Apr 1;122(7):1684-5.
137. Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, et al. 
FUTURE I and II Study Group. Adenocarcinoma in situ and associated 
human papillomavirus type distribution observed in two clinical trials of a 
quadrivalent human papillomavirus vaccine. Int J Cancer. 2011 Mar 
15;128(6):1344-53. doi: 10.1002/ijc.25723. Epub 2011 Jan 12 
138. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, et al. 
Japan HPV And Cervical Cancer Study Group.Predicting the progression 
of cervical precursor lesions by human papillomavirus genotyping: a 
prospective cohort study. Int J Cancer. 2011 Jun 15;128(12):2898-910. 
doi: 10.1002/ijc.25630. Epub 2010 Oct 13
72 
139. Shepherd J., Peersman G., Weston R. and Napuli I. Cervical cancer and 
sexual lifestyle: a systematic review of health education interventions 
targeted at women. Health Education Research. 2000:15,681–694. 
140. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. 
Condom use and the risk of genital human papillomavirus infection in 
young women. N Engl J Med. 2006 Jun 22;354(25):2645-54
141. Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, et al. 
Disassembly and reassembly of yeast-derived recombinant human 
papillomavirus virus-like particles (HPV VLPs). J Pharm Sci. 2006 
Oct;95(10):2195-206. 
142. Bryan JT .Developing an HPV vaccine to prevent cervical cancer and 
genital warts. Vaccine. 2007 Apr 20;25(16):3001-6. Epub 2007 Jan 18. 
Review 
143. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, et 
al. Immunological analyses of human papillomavirus capsids. Vaccine. 
2001 Feb 8;19(13-14):1783-93.
144. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et 
al. Broad Spectrum HPV Vaccine Study A 9-valent HPV vaccine against 
infection and intraepithelial neoplasia in women.N Engl J Med. 2015 Feb 
19;372(8):711-23. doi: 10.1056/NEJMoa1405044. 
145. Villa LL. HPV prophylactic vaccination: The first years and what to 
expect from now. Cancer Lett. 2011 Jun 28;305(2):106-12. doi: 
10.1016/j.canlet.2010.12.002. Epub 2010 Dec 28. Review. 
146. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et 
al. HPV-010 Study Group.Comparison of the immunogenicity and safety 
of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer 
vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009 
Oct;5(10):705-19. Epub 2009 Oct 14. 
147. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon 
D. 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus 
guidelines for the management of women with abnormal cervical 
screening tests. J Low Genit Tract Dis. 2007 Oct;11(4):201-22. Erratum 
in: J Low Genit Tract Dis. 2008 Jul;12 
73 
148. Giuliano AR, Nyitray AG, Kreimer AR et al. EUROGIN 2014 roadmap: 
differences in human papillomavirus infection natural history, 
transmission and human papillomavirus-related cancer incidence by 
gender and anatomic site of infection. Int J Cancer. 2015; 136:2752-60.
149. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N,
Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 
capsid antibody responses following incident infection. J Infect Dis. 2000 
Jun;181(6):1911-9. Epub 2000 May 31. 
150. Fish EN. The X-files in immunity: sex-based differences predispose 
immune responses. Nat Rev Immunol.  2008; 8:737–44. 
151. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. 
2003 Aug;3(8):469-75. Review 
152. Franco EL, Harper DM. Vaccination against human papillomavirus 
infection: a new paradigm in cervical cancer control. Vaccine. 2005 Mar 
18;23(17-18):2388-94. Review
153. Huang S, Tang N, Mak WB, Erickson B, Salituro J, Li Y, et al. Principles 
and analytical performance of Abbott RealTime High Risk HPV test. J 
Clin Virol. 2009;45:S13 – 17.
154. Poljak M, Ostrbenk A, Seme K, Ucakar V, Hillemanns P, Bokal EV, et al.
Comparison of clinical and analytical performance of the Abbott Realtime 
High Risk HPV test to the performance of hybrid capture 2 in population-
based cervical cancer screening. J Clin Microbiol. 2011;49:1721 – 9.
155. Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E.
The Abbott RealTime High Risk HPV test: comparative evaluation of 
analytical specificity and clinical sensitivity for cervical carcinoma and 
CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta 
Dermatovenerol Alp Pannonica Adriat 2009;18:94 – 103. 
156. Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P,
et al. Comparison of clinical performance of Abbott RealTime High Risk 
HPV test with that of hybrid capture 2 assay in a screening setting. J Clin 
Microbiol. 2011;49:1446 – 51
157. Kocjan BJ, Poljak M, Seme K. Universal ProbeLibrary based real-time 
PCR assay for detection and confirmation of human papillomavirus 
genotype 52 infections. J Virol Methods. 2010;163:492 – 4.
74 
158. Coutlée F, Rouleau D, Ghattas G, Hankins C, Vézina S, Coté P, et al.
Confirmatory real-time PCR assay for human papillomavirus (HPV) type 
52 infection in anogenital specimens screened for HPV infection with the 
linear array HPV genotyping test. J Clin Microbiol. 2007 
Nov;45(11):3821-3. Epub 2007 Sep 26 
159. Marks M, Gupta SB, Liaw KL, Kim E, Tadesse A, Coutlee F, et al.
Confirmation and quantitation of human papillomavirus type 52 by Roche 
Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time 
PCR. J Virol Methods. 2009 Mar;156(1-2):152-6. doi: 
10.1016/j.jviromet.2008.10.013. Epub 2008 Dec 6 
160. Kovanda A, Juvan U, Sterbenc A, Kocjan BJ, Seme K, Jancar N, et al.
Pre-vaccination distribution of human papillomavirus (HPV) genotypes in 
women with cervical intraepithelial neoplasia grade 3 (CIN 3) lesions in 
Slovenia. Acta Dermatovenerol Alp Pannonica Adriat. 2009 
Jun;18(2):47-52
161. Ferlay J, Shin HR, Bray F, et al. Estimates of worlwide burden of cancer 
in 2008: Globocon 2008. Int J Cancer. 2010;127, 2893-917. 
162. Comprehensive cervical cancer control A guide to essential practice; 
WHO Library Cataloguing-in-Publication Data Comprehensive cervical 
cancer control: a guide to essential practice – 2nd ed, December 2014
163. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et 
al. Worldwide prevalence and genotype distribution of cervical human 
papillomavirus DNA in women with normal cytology: a meta-
analysis. Lancet Infect Dis. 2007;7(7):453–459. doi: 10.1016/S1473-
3099(07)70158-5.
164. Alemany L, de Sanjosé S, Tous S, Quint W, Vallejos C, Shin HR, et al. 
RIS HPV TT Study Group. Time trends of human papillomavirus types in 
invasive cervical cancer, from 1940 to 2007. Int J Cancer. 2014 Jul 
1;135(1):88-95. doi: 10.1002/ijc.28636. Epub 2013 Dec 30 
165. Trottier H, Franco EL.Human. Papillomavirus and cervical cancer: 
burden of illness and basis for prevention. Am J Manag Care. 2006 
Dec;12(17 Suppl):S462-72
75 
166. Cornet I, Bouvard V, Campo MS, Thomas M, Banks L, Gissmann L, et 
al. Comparative analysis of transforming properties of E6 and E7 from 
different beta human papillomavirus types. J Virol. 2012 Feb;86(4):2366-
70. doi: 10.1128/JVI.06579-11. Epub 2011 Dec 14.
167. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of 
cancer attributable to HPV by site, country and HPV type. Int J Cancer. 
2017 Aug 15;141(4):664-670. doi: 10.1002/ijc.30716. Epub 2017 Jun 8. 
168. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et 
al. IARC HPV Prevalence Surveys Study Group.Worldwide distribution of 
human papillomavirus types in cytologically normal women in the 
International Agency for Research on Cancer HPV prevalence surveys: 
a pooled analysis. Lancet. 2005 Sep 17-23;366(9490):991-8 
169. Andonovska J. Genotypic distribution and prevalence of the HPV 
infection in Macedonia. 16th ICID Abstracts / International Journal of 
Infectious Diseases 21S (2014) 1–460. 
170. Kovacevic G, Nikolic N, Jovanovic-Galovic A, Hrnjakovic-Cvjetkovic 
I, Vuleta D, Patic A, et al.. Frequency of twelve carcinogenic human 
papilloma virus types among women from the South Backa region, 
Vojvodina, Serbia. Turk J Med Sci. 2016 Jan 5;46(1):97-104. doi: 
10.3906/sag-1410-47.
171. Poljak M, Seme K, Maver P, Kocjan B, Cuschieri K, Rogovskaya S, Marc 
et al . Human papillomavirus prevalence and type-distribution, cervical 
cancer screening practices and current status of vaccination 
implementation in central and eastern europe. Vaccine. 2013; 31 Suppl 
7: H59-H70 Dec.
172. Filipi K, Tedeschini A, Paolini F, Celicu S, Morici S, et al. Genital human 
papillomavirus infection and genotype prevalence among Albanian 
women: a cross-sectional study. J Med Virol. 2010 Jul;82(7):1192-6. doi: 
10.1002/jmv.21803 
173. Grahovac M, Racić I, Hadzisejdić I, Dorić A, Grahovac B. Prevalence of 
human papillomavirus among Croatian women attending regular 
gynecological visit. Coll Antropol. 2007 Apr;31 Suppl 2:73-7.
76 
174.  Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Lüthge A,
et al. Prevalence of high-risk HPV types and associated genital diseases 
in women born in 1988/89 or 1983/84 – results of WOLVES, a 
population-based epidemiological study in Wolfsburg, Germany.  BMC 
Infect Dis. 2013; 13: 135. Published online 2013 Mar 
13. doi: 10.1186/1471-2334-13-135
175. Mollers M, Boot Hein J, Vriend Henrike J, King Audrey J, van den Broek 
Ingrid VF, van Bergen Jan EA, et al. Prevalence, incidence and 
persistence of genital HPV infections in a large cohort of sexually active 
young women in the Netherlands. Vaccine. 2013 Jan 2;31(2):394-401. 
doi: 10.1016/j.vaccine.2012.10.087. Epub 2012 Nov 10. 
176. Kovachev S, Slavov V, Slavova K. Prevalence of human papillomavirus 
infection in women in some cities and regions of Bulgaria. J Med Virol. 
2013;85:1577 – 84. 
177. Tachezy R, Smahelova J, Kaspirkova J, Salakova M. Human 
papillomavirus type-specific prevalence in the cervical cancer screening 
population of Czech women. PLoS One. 2013;8:e79156.
178. Moga MA, Irimie M, Oanta A, Pascu A, Burtea V. Type-specific 
prevalence of human papillomavirus by cervical cytology among women 
in Brasov, Romania. Asian Pac J Cancer Prev. 2014;15:6887 – 92.
179. Duvlis S, Popovska-Jankovic K, Arsova ZS, Memeti S, Popeska Z, 
Plaseska-Karanfilska D. HPV E6/E7 mRNA versus HPV DNA biomarker 
in cervical cancer screening of a group of Macedonian women. J Med 
Virol. 2015;87:1578 – 86. 
180. Simanaviciene V, Gudleviciene Z, Popendikyte V, Dekaminaviciute D, 
Stumbryte A, Rubinaite V,et al. Studies on the prevalence of oncogenic 
HPV types among Lithuanian women with cervical pathology. J Med 
Virol. 2015;87:461 – 71.
181. Kovacevic G, Nikolic N, Jovanovic-Galovic A, Hrnjakovic-Cvjetkovic I, 
Vuleta D, Patic A, et al. Frequency of twelve carcinogenic human 
papilloma virus types among women from the South Backa region, 
Vojvodina, Serbia. Turk J Med Sci 2016;46:97 – 104. 
77 
182. Staykova J, Belovska T, Murad A, Kakid S, Nacheva A, Shikova E. 
Cervical Viral Infections among Asymptomatic Bulgarian Women. Cent 
Eur J Public Health. 2016;24:176 – 9.
183. Sabol I, Milutin Gašperov N, Matovina M, Božinović K, Grubišić G, 
Fistonić I, et al. Cervical HPV type-specific pre-vaccination prevalence 
and age distribution in Croatia. PLoS One 2017;12:e0180480. 
184. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, 
Parkin DM, et al. Cancer incidence and mortality worldwide: sources, 
methods and major patterns in GLOBOCAN 2012. Int J Cancer 
2015;136:E359 – 86.
185. Učakar V, Poljak M, Klavs I. Pre-vaccination prevalence and distribution 
of high-risk human papillomavirus (HPV) types in Slovenian women: a 
cervical cancer screening based study. Vaccine. 2012;30:116 – 20.
186. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, 
Bruni L, et al. Global burden of human papillomavirus and related 
diseases. Vaccine. 2012;30:F12 – 23.
187. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. 
WHO International Agency for Research on Cancer Monograph Working 
Group. A review of human carcinogens–part B: biological agents. Lancet 
Oncol. 2009;10:321 – 2.
188. Cubie HA. Diseases associated with human papillomavirus infection. 
Virology. 2013;445:21 – 34.
189. Manga MM, Fowotade A, Abdullahi YM, El-Nafaty AU, Adamu DB, 
Pindiga HU, et al. Epidemiological patterns of cervical human 
papillomavirus infection among women presenting for cervical cancer 
screening in North-Eastern Nigeria. Infect Agent Cancer. 2015;10:39.
190. Louie KS, de Sanjose S, Diaz M, Castellsagué X, Herrero R, Meijer CJ,
et al. International Agency for Research on Cancer Multicenter Cervical 
Cancer Study Group. Early age at first sexual intercourse and early 
pregnancy are risk factors for cervical cancer in developing countries. Br 
J Cancer. 2009;100:1191 – 7.
191. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi 
S, et al. International Agency for Research on Cancer Multicenter 
Cervical Cancer Study Group. Worldwide human papillomavirus etiology
78 
of cervical adenocarcinoma and its cofactors: implications for screening 
and prevention. J Natl Cancer Inst. 2006 Mar 1;98(5):303-15.
192. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, et al.
Sexual behaviour and smoking as determinants of cervical HPV infection 
and of CIN3 among those infected: a case-control study nested within 
the Manchester cohort, Br J Cancer. 2000 Dec;83(11):1565-72
193. Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani 
S, et al. Risk factors for high-risk human papillomavirus infection and 
cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer.
2011 Dec;21(9):1654-63. doi: 10.1097/IGC.0b013e3182288104. 
194. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al.
International Agency for Research on Cancer. Multicentric Cervical 
Cancer Study Group. Role of parity and human papillomavirus in cervical 
cancer: the IARC multicentric case-control study. Lancet. 2002;359:1093 
– 101.
195. Gargano JW, Nisenbaum R, Lee DR, Ruffin MT 4th, Steinau M, Horowitz 
IR, et al. Age-group differences in human papillomavirus types and 
cofactors for cervical intraepithelial neoplasia 3 among women referred 
to colposcopy. Cancer Epidemiol Biomarkers Prev. 2012;21:111 – 21. 
196. Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, et 
al. The Influence of Hormonal Factors on the Risk of Developing Cervical 
Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One. 2016 
Jan 25;11(1):e0147029. doi: 10.1371/journal.pone.0147029. eCollection 
2016 
197. Ferrera A, Velema JP, Figueroa M, Bulnes R, Toro LA, Claros JM, et al.
Co-factors related to the causal relationship between human 
papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol. 
2000 Oct;29(5):817-25.
198. Castle PE, Walker JL, Schiffman M, Wheeler CM. Hormonal 
contraceptive use, pregnancy and parity, and the risk of cervical 
intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women 
with equivocal or mildly abnormal cytology. Int J Cancer. 2005 Dec 
20;117(6):1007-12.
79 
199. Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. 
Parity as a cofactor for high-grade cervical disease among women with 
persistent human papillomavirus infection: a 13-year follow-up. Br J 
Cancer. 2013 Jan 15;108(1):234-9. doi: 10.1038/bjc.2012.513. Epub 
2012 Nov 20. 
200. Autier P, Coibion M, Huet F, Grivegnee AR. Transformation zone 
location and intraepithelial neoplasia of the cervix uteri. Br J Cancer.
1996 Aug;74(3):488-90.
201. Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJ, Clifford 
GM, et al. IARC HPV Prevalence Surveys Study Group. Sexual 
behaviour, condom use, and human papillomavirus: pooled analysis of 
the IARC human papillomavirus prevalence surveys. Cancer Epidemiol 
Biomarkers Prev. 2006 Feb;15(2):326-33. 
202. International Collaboration of Epidemiological Studies of Cervical 
Cancer, Appleby P, Beral V, Berrington de González A, Colin D,
Franceschi S, Goodhill A, et al. Cervical cancer and hormonal 
contraceptives: collaborative reanalysis of individual data for 16,573 
women with cervical cancer and 35,509 women without cervical cancer 
from 24 epidemiological studies. Lancet. 2007 Nov 10;370(9599):1609-
21.
203. Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A, et al. The 
association of hormonal contraceptive use and HPV prevalence. Int J 
Cancer. 2011 Jun 15;128(12):2962-70. doi: 10.1002/ijc.25628. Epub 
2010 Oct 26.
204. Marks MA, Gravitt PE, Burk RD, Studentsov Y, Farzadegan H, Klein SL.
Progesterone and 17beta-estradiol enhance regulatory responses to 
human papillomavirus type 16 virus-like particles in peripheral blood 
mononuclear cells from healthy women, Clin Vaccine Immunol. 2010 
Apr;17(4):609-17. doi: 10.1128/CVI.00441-09. Epub 2010 Feb 3. 
205. Kim CJ, Um SJ, Kim TY, Kim EJ, Park TC, Kim SJ, et al. Regulation of 
cell growth and HPV genes by exogenous estrogen in cervical cancer 
cells. Int J Gynecol Cancer. 2000 Mar;10(2):157-164. 
80 
206. Ruutu M, Wahlroos N, Syrjänen K, Johansson B, Syrjänen S. Effects of 
17beta-estradiol and progesterone on transcription of human 
papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J 
Gynecol Cancer. 2006 May-Jun;16(3):1261-8 
207. Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 
oncogene dysregulates the cell cycle and contributes to cervical 
carcinogenesis through two independent activities. Cancer Res. 2007 
Feb 15;67(4):1626-35. 
208. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, 
and malignant progression of cervical cancer in a human papillomavirus-
transgenic mouse model. Proc Natl Acad Sci U S A. 2005 Feb 
15;102(7):2490-5. Epub 2005 Feb 7. 
209. Lam JUH, Rebolj M, Dugué PA et al. Condom use in prevention of 
Human Papillomavirus infections and cervical neoplasia: systematic 
review of longitudinal studies. J Med Screen vol. 21, (1) 38-50, 2014.
210. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, 
external genital warts, or cervical neoplasia? A meta-analysis, Sex 
Transm Dis. 2002 Nov;29(11):725-35. 
211. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al.
Condom use and the risk of genital human papillomavirus infection in 
young women. N Engl J Med. 2006 Jun 22;354(25):2645-54. 
212. Chih HJ, Lee AH, Colville L, Xu D, Binns CW. Condom and oral 
contraceptive use and risk of cervical intraepithelial neoplasia in 
Australian women. Gynecol Oncol. 2014 Jul;25(3):183-7. doi: 
10.3802/jgo.2014.25.3.183. Epub 2014 Jul 3 
213. Mitra S, Study of the risk factors for cancer cervix in a specialty hospital 
in Kolkata. J Com Med. 2009;5: 1-5.
214. Ashrafi GH, Haghshenas M, Marchetti B, Campo MS. E5 protein of 
human papillomavirus 16 downregulates HLA class I and interacts with 
the heavy chain via its first hydrophobic domain. Int J Cancer. 2006 Nov 
1;119(9):2105-12. 
81 
215. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus 
carcinogenesis--role of parity, oral contraceptives, and tobacco smoking.
J Natl Cancer Inst Monogr. 2003;(31):20-8. Review. 
216. Bayo S, Bosch FX, de Sanjosé S, Muñoz N, Combita AL, Coursaget P, 
et al. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol. 
2002 Feb;31(1):202-9.
217. Forman D, de Martel C, Lacey C, Soerjomataram I, Lortet-Tieulent J, 
Bruni L, et al. Global burden of human papillomavirus and related 
diseases. Vaccine. 2012;30 (Suppl. 5): F12–F23.
218. Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veerus P, Plummer M, 
et al. Preventable fractions of cervical cancer via effective screening in 
six Baltic, central, and eastern European countries 2017-40: a 
population-based study. Lancet Oncol. 2016 Oct;17(10):1445-1452. doi: 
10.1016/S1470-2045(16)30275-3. Epub 2016 Aug 23.
219. Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available 
molecular tests for human papillomaviruses (HPV): 2015 update. J Clin 
Virol. 2016 Mar;76 Suppl 1:S3-S13. doi: 10.1016/j.jcv.2015.10.023. Epub 
2015 Nov 5.
220. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female 
human papillomavirus vaccination in 179 countries: a PRIME modelling 
study. Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-
109X(14)70237-2. Epub 2014 Jun 9. 
221. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et 
al. Global estimates of human papillomavirus vaccination coverage by 
region and income level: a pooled analysis. Lancet Glob Health. 2016 
Jul;4(7):e453-63. doi: 10.1016/S2214-109X(16)30099-7.
82 
11. LIST OF TABLES AND FIGURES
TABLES 
Table 1. Socio-demographic characteristics of women included in the 
study 
Table 2. Characteristics of women included in the study – health issues 
Table 3. Cytology results of the women involved in the research
Table 4. Overall distribution of HR-HPV types among 199 women from 
Kosovo
Table 5. Overall prevalence of HR-HPVs among 199 women from Kosovo 
according to the cytology results 
Table 6. Distribution of HR-HPV types among 26 women infected with any 
of the 14 HR-HPVs according to the cytology results 
Table 7. Association between socio-demographic characteristics and HPV 
infection (results of an univariate logistic regression analysis) 
Table 8. Association between current age, age at 1st sexual intercourse, 
number of partners and HPV infection (results of multiple logistic regression 
model).
Table 9. Association between socio-demographic characteristics and HR-
HPV types (results of likelihood ratio test). 
Table 10. Correlation between the profession and HPV positivity
Table 11. Menarche and Menstrual cycle regularity and HPV positivity
Table 12. Contraception and HPV infection
Table 13. Correlation between HPV infection and the previous history of 
cervical screening
83 
FIGURES 
Figure 1. Classification of Papillomaviridae 
Figure 2. The genome of HPV 
Figure 3. Role of E6 and E7 oncoproteins 
Figure 4. The impact of HPV infection on squamous epithelia
Figure 5a.  Genotyping strips produced after LINEAR ARRAY HPV testing 
Figure 5b. Genotyping strips produced after LINEAR ARRAY HPV testing
Figure 6. Percentages of identified HR-HPV types 
Figure 7. Age-specific HPV prevalence with standard deviation among 199 
women from Kosovo included in the study 
Figure 8. Among women younger than 40 the prevalence is 20% (95% CI: 
11 – 29%) and among older 8% (95%CI: 3 – 13%) 
Figure 9: Percentage of women by important factors associated with HPV 
infection 
Figure 10:   Odds ratios with 95 % confidence intervals for all relevant 
parameters. 
84 
12. CANDIDATE’S CURRICULUM VITAE
Pranvera Zejnullahu Raçi was born on 26th of March, 1976 in Prishtina, 
Republic of Kosovo. 
She finished the School of Medicine in the University of Prishtina, 
and later on she continued her further professional education, 
specializing in the field of Gynaecology and Obstetrics in the University 
Clinical Centre of Kosovo. While working as a gynaecologist, she 
gained interest in a field of Gynaecological Oncology and cervical 
diseases prevention. 
Due to her interests in this area she continued with PhD studies, in a 
field of Biomedicine and Health Sciences in the School of Medicine, 
University of Zagreb. 
Pranvera is a co-author in few publications in international journals and 
participant at different medical congresses and conferences, in country 
and abroad. 
In her research, she has tried to reveal a real situation with HPV 
infection, necessity of implementing a proper cervical cancer screening 
program in Kosovo, as well as possibility for starting the vaccination 
against the HPV.  
This research has a great contribution for Public Health in 
Kosovo, in sense of having a clear picture on hr-HPV infection, and the 
distribution of certain HPV types among the female population of 
Kosovo. This study may also serve as a starting point for having into 
consideration vaccination against HPV in near future.
